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ABSTRACT 
Harnessing Inflammatory Signaling to Promote Bone Regeneration and 
Mitigate Joint Damage 
by 
Paschalia Maria Mountziaris 
Inflammatory processes are infamous for their destructive effects on tissues and 
joints in a variety of diseases. Within the body, inflammation is a highly regulated 
biological response whose purpose is to promote tissue regeneration following injury. 
However, in certain settings, inflammation persists and leads to progressive tissue 
destruction. This thesis focused on modulating inflammatory signaling in both contexts. 
Part I investigated the effects of a model pro-inflammatory cytokine, tumor necrosis 
factor-alpha (TNF-a), on the in vitro osteogenic differentiation of mesenchymal stem 
cells (MSCs). In contrast, Part II describes the development and in vivo evaluation ofthe 
first intra-articular controlled release system for the temporomandibular joint (TMJ), 
which silences inflammatory signaling and thus mitigates the painful joint damage seen 
in inflammatory TMJ disease. The following specific aims were addressed: (1) to 
determine the concentration of TNF -a that enhances in vitro osteogenic differentiation of 
MSCs; (2) to determine the temporal pattern of TNF -a delivery that enhances in vitro 
osteogenic differentiation of MSCs; (3) to determine the impact of bone-like extracellular 
matrix (ECM) on the concentration and temporal pattern of TNF -a delivery that enhances 
in vitro osteogenic differentiation of MSCs; ( 4) to evaluate the biocompatibility of intra-
articular microparticles in the rat TMJ; (5) to develop a microparticle-based formulation 
111 
for sustained release of a model anti-inflammatory small interfering ribonucleic acid 
(siRNA); and (6) to evaluate the therapeutic efficacy of intra-articular microparticles 
delivering siRNA in an animal model of TMJ inflammation. These studies led to the 
development of powerful strategies to rationally control inflammation to promote bone 
regeneration and mitigate joint damage in the setting of disease, both of which will 
ultimately improve the quality and specificity of therapies available in modem medicine. 
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Chapter 1 
Introduction and Objectives 
Inflammatory processes are infamous for their destructive effects on tissues and 
joints in a variety of diseases. Within the body, inflammation is a highly regulated 
biological response whose purpose is to promote tissue regeneration following injury. 
However, in certain settings, inflammation persists and leads to progressive tissue 
destruction. The studies presented in this thesis focused on modulating inflammatory 
signaling in both contexts. Part I (Chapters 2-6) of the thesis investigated the effects of a 
pro-inflammatory cytokine, tumor necrosis factor-alpha (TNF-a), on the in vitro 
osteogenic differentiation of mesenchymal stem cells. In contrast, Part II (Chapters 7-1 0) 
describes the development of a novel intra-articular controlled release system to silence 
inflammatory signaling and prevent painful joint degeneration seen in inflammatory 
temporomandibular joint disease. 
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The goal of the studies described in Part I was to characterize the effects of a pro-
inflammatory cytokine, tumor necrosis factor alpha (TNF-a), on the osteogenic 
differentiation of mesenchymal stem cells (MSCs). TNF-a was selected as a model 
inflammatory signal for these studies based on its significant impact on in vivo bone 
regeneration (1, 2). We hypothesized that delivery of TNF-a would enhance the 
osteogenic differentiation of MSCs. Due to the many gaps in our knowledge regarding 
the mechanism by which inflammatory signals trigger regeneration, the studies described 
in this thesis were conducted entirely in vitro and focused on establishing the optimal 
parameters for a novel tissue engineering strategy to rationally control inflammation and 
trigger osteogenesis at the site of a large bone injury. 
In vitro osteogenic differentiation of mesenchymal stem cells typically involves 
the addition of dexamethasone, an anti-inflammatory agent that might mask the effects of 
TNF-a (3-5). Our laboratory has developed a method that supports continued in vitro 
osteogenic differentiation of MSCs without the need for dexamethasone; MSCs expanded 
in the presence of dexamethasone experience continued osteogenic differentiation in the 
absence of dexamethasone by means of a 3D porous scaffold containing pre-generated 
bone-like extracellular matrix (ECM) (6-11). The studies described herein established the 
optimal dosage and temporal pattern of delivery of TNF -a to enhance osteogenic 
differentiation ofMSCs cultured in a 3D biodegradable polymer scaffold. 
The goal of the studies in Part II of this thesis was to develop an intra-articular 
sustained release system to treat painful temporomandibular joint (TMJ) inflammation. 
TMJ disorders are a heterogeneous group of disorders that are characterized by painful, 
progressive joint degeneration. Although TMJ disorders are typically non-inflammatory 
2 
in origin, joint inflammation commonly appears as the disorder progresses, and this 
worsens the painful symptoms and also appears to accelerate destruction of TMJ tissue 
(12). The ultimate goal of the studies described herein was to develop a sustained release 
system for a model anti-inflammatory agent, a small interfering RNA (siRNA) sequence 
that silences inflammatory signaling. 
A sustained release system was a critical component of the design because it 
addresses a major limitation of current intra-articular injectable formulations used to treat 
severe, painful TMJ degeneration: rapid clearance of injected agents, which necessitates 
frequent injections that carry a high risk of iatrogenic joint injury (12, 13). Although 
numerous drug delivery systems have been developed for various applications, including 
intra-articular controlled release in large joints like the knee (see summary in Table 7.1), 
no sustained release systems had been developed for the TMJ (13) prior to the studies 
described in this thesis. 
The following specific aims were investigated: 
Specific Aim 1 
To determine the concentration of TNF-a that enhances in vitro osteogenic 
differentiation of MSCs. Osteogenic differentiation of MSCs was triggered via 
preculture with osteogenic supplements, including dexamethasone. MSCs were then 
seeded onto 3D biodegradable polymeric meshes and varying doses of TNF-a were 
delivered in the absence of dexamethasone (14). 
3 
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Specific Aim 2 
To determine the temporal pattern of TNF -a delivery that enhances in vitro 
osteogenic differentiation of MSCs. Using the optimal dosage established in Specific 
Aim 1, these studies established the optimal temporal pattern of 1NF -a delivery (early, 
intermediate, late, or continuous) to promote osteogenic differentiation of MSCs. In 
parallel, since Specific Aim 1 indicated that 1NF-a supports continued osteogenic 
differentiation of MSCs in the absence of dexamethasone, these studies investigated 
whether 1NF -a was sufficient to trigger osteogenic differentiation of dexamethasone-
naYveMSCs. 
Specific Aim 3 
To determine the impact of bone-like ECM on the concentration and temporal 
pattern of TNF -a delivery that enhances in vitro osteogenic differentiation of MSCs. 
The studies in Specific Aims 1 and 2 provided the optimal 1NF -a delivery parameters for 
osteogenic differentiation of MSCs and indicated that 1NF -a supports, but does not 
induce, osteogenic differentiation. To create a more realistic in vitro model of the injured 
bone microenvironment and explore the interplay of 1NF-a and bone-like ECM, varying 
doses of 1NF-a were delivered to osteogenically differentiating MSCs cultured in vitro 
on 3D biodegradable microfiber scaffolds containing pregenerated bone-like ECM. 
4 
Specific Aim 4 
To evaluate the biocompatibility of intra-articular microparticles in the rat TMJ. 
We were particularly cautious in the development of a sustained release system for the 
TMJ due to the lack of previous data regarding TMJ tissue response and also because of 
the terrible history of early alloplastic (Proplast-Teflon) TMJ implants; their 
susceptibility to mechanical failure gave rise to Teflon microparticles that induced severe 
foreign body immune reactions and massive TMJ damage (15). Thus, the first step was to 
evaluate the in vivo biocompatibility of the carrier material, poly(DL-lactic-co-glycolic 
acid) microparticles (PLGA MPs), and determine the impact of PLGA MP concentration 
on healthy TMJ function (16). 
Specific Aim 5 
To develop a microparticle-based formulation for sustained release of a model anti-
inflammatory small interfering ribonucleic acid (siRNA). As the next step in the 
development of an intra-articular controlled release system to treat painful TMJ 
inflammation, we developed several PLGA MP formulations encapsulating polyplexes 
consisting of siRNA and branched poly( ethylenimine) (PEl), which is a common 
polymeric transfecting agent. The effect of siRNA loading, as well as the effect of the 
relative amounts of PEl and siRNA, on the release kinetics of siRNA-PEI polyplexes was 
determined. The size and the relative PEl-to-siRNA content of the polyplexes released 
over time were also characterized (17). 
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Specific Aim 6 
To evaluate the therapeutic efficacy of intra-articular PLGA MPs delivering siRNA-
PEI polyplexes in an animal model of TMJ inflammation. Although several 
inflammatory mediators, including 1NF-a and type G immunoglobulins (lgGs) are 
elevated in the TMJs of patients and animal models with painful inflammation (18-20), 
injection of these agents does not reproduce the severe inflammation seen in TMJ 
disorders. For example, intra-articular injection of 1NF-a yields only mild inflammation 
in animal models, requiring the injection of an irritant to establish an animal model of 
joint inflammation (21). In this study, we used Complete Freund's Adjuvant (CFA), a 
severely irritating water-in-oil emulsion containing killed Mycobacterium tuberculosis 
and paraffin oil, to induce inflammation in the rat TMJ. This is an established, optimized 
method of establishing a model of TMJ inflammation (22-27). This joint disease model 
then received PLGA MPs loaded with anti-inflammatory-siRNA-PEI polyplexes, to 
evaluate the efficacy of the first intra-articular sustained release system for the TMJ. 
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Part 1: 
Harnessing Inflammatory Signaling to Promote 
Bone Regeneration 
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Chapter 2 
Background: Modulation of the Inflammatory 
Response for Enhanced Bone Tissue 
Regeneration1'2 
Abstract: Pro-inflammatory cytokines are infamous for their catabolic effects on tissues 
and joints in both inflammatory diseases and following the implantation of biomedical 
devices. However, recent studies indicate that many of these same molecules are critical 
for triggering tissue regeneration following injury. This review will discuss the role of 
inflammatory signals in regulating bone regeneration and the impact of both 
1 This chapter was published as: Mountziaris PM, Mikos AG. Modulation of the inflammatory response for 
enhanced bone tissue regeneration. Tissue Eng Part B Rev 2008;14(2):179-186. 
2 A second manuscript detailing advances in the field from 2008-2011 is included in the next chapter. 
3 This chapter will be published as: Mountziaris PM, Spicer PP, Kasper FK, Mikos AG. Harnessing and 
2 A second manuscript detailing advances in the field from 2008-2011 is included in the next chapter. 
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immunomodulatory and anti-inflammatory pharmacologic agents on fracture healing, to 
demonstrate the importance of incorporating rational control of inflammation into the 
design of tissue engineering strategies. 
2.1. Introduction 
The limitations of current bone reconstruction techniques have led to increased 
interest in bone tissue engineering. Bone has the remarkable capacity to heal without scar 
formation, but this regenerative process fails in patients with large bone lesions or 
impaired wound healing, requiring clinical intervention. Autologous bone grafts are the 
current gold standard solution to repair critical size bone defects, but their use is limited 
by the availability of suitable donor tissue. Another problem is the necessity for a second 
surgery to harvest graft tissue, with potentially severe complications such as hemorrhage, 
nerve damage, infection, and deformity. Bone tissue engineering has emerged as a new 
interdisciplinary strategy to promote healing of large bone defects using bioactive 
implantable materials. Cells and bioactive factors are incorporated into these scaffolds to 
provide temporal and spatial cues guiding bone regeneration (28, 29). The rational design 
of these scaffolds is informed by cell and developmental biology, which provide 
increasingly detailed knowledge of the cellular and molecular signals directing bone 
healing. 
Fracture healing involves complex molecular signaling and induces significant 
changes in the expression of several thousand genes (30, 31). To develop an effective 
tissue engineering strategy for bone regeneration, the "master switches" controlling this 
process must be identified and incorporated (32). The importance of osteogenic factors, 
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including bone morphogenetic proteins, in bone regeneration is well known, and they are 
consequently widely used in bone tissue engineering systems, though with limited 
success. However, the critical role of pro-inflammatory cytokines in initiating 
regeneration remains poorly recognized in both biology and tissue engineering (33, 34). 
As such, to our knowledge, limited work has been done in tissue engineering to harness 
inflammatory signaling. This review will discuss the role of inflammatory signals in 
regulating bone regeneration and the impact of anti-inflammatory and 
immunomodulatory pharmacologic agents on fracture healing, to demonstrate the 
importance of incorporating rational control of inflammation into the design of tissue 
engineering strategies. 
2.2. Bone Regeneration Following Injury: An Overview of Molecular 
Signaling 
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Bone fractures heal by either a direct (primary) or an indirect (secondary) 
mechanism. Primary healing refers to direct tunneling of remodeling units from the 
cortex across the fracture line and into the cortex on the other side. This type of healing is 
rare, as it requires that fracture fragments be restored to their original anatomic location 
and rigidly stabilized at the site. Since typical treatments, e.g. plaster cast placement, do 
not completely immobilize the injured bone, fractures typically heal by secondary healing 
(35, 36). This process involves overlapping phases of inflammation, renewal, and 
remodeling. 
2.2.1. Inflammatory Phase 
Bone fracture is an injury, and thus incites an inflammatory response, which 
peaks 24 hours following the injury and is complete by the first week (3 7). During this 
time, a complex cascade of pro-inflammatory signals and growth factors are released in a 
temporally and spatially controlled manner (38). Levels of several inflammatory 
mediators, including IL-l, IL-6, IL-11, IL-18, and 1NF -a, are significantly elevated 
within the first few days (30, 38). These signals recruit inflammatory cells and promote 
angiogenesis (38, 39). Platelets are activated by injury to blood vessels at the fracture 
site, and release TGF-~1 and PDGF. Osteoprogenitor cells at the fracture site express 
bone morphogenetic proteins (37, 40). These factors, along with inflammatory mediators, 
recruit mesenchymal stem cells and then guide their differentiation and proliferation (35, 
41, 42). 
2.2.2. Renewal Phase 
At the periphery of the fracture site, stem cells differentiate into osteoblasts. As a 
result, bone forms via intramembranous ossification 7-10 days after injury (35). 
Chondrogenesis occurs in the bulk of the injured tissue, which is mechanically less stable 
(37, 42). Inflammatory mediators are absent during this phase. TGF-~2 and -~3, bone 
morphogenetic proteins, and other molecular signals induce endochondral bone formation 
in the cartilaginous callus (37, 38). The cartilage calcifies, and then is replaced with 
woven bone (39, 41). 
2.2.3. Remodeling 
Osteoprogenitor cells differentiate into osteoblasts, which express IL-l, IL-6, and 
IL-11, and other factors that promote osteoclast formation ( 41 ). The renewing and 
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resorptive actions of these two cell types replace the initial woven bone with lamellar 
bone. This remodeling phase is regulated by several pro-inflammatory signals. In 
addition to IL-l, IL-6, and IL-11, elevated levels of TNF -a, IL-12, and IFN -y are also 
detectable at the fracture site (30, 38). Rodent and porcine models indicate that growth 
hormone and parathyroid hormone also play key roles in this phase, speeding healing and 
strengthening the fracture callus ( 43-46). Although the original structure and mechanical 
properties of the skeleton are restored within several weeks of fracture, molecular and 
cellular signaling can take up to several years to return to its normal state. In human 
patients, hormones regulating bone metabolism remain at elevated levels for up to one 
year after hip fracture (47). Bone turnover is significantly accelerated in humans for at 
least 6 months following bone fracture, and does not return to baseline for several years 
(47-51). 
2.2.4. Comparison to embryonic bone development 
Although fracture healing is very similar to skeletogenesis in the developing 
embryo, there are key differences in the regulation of each process. Mechanical 
stimulation has a unique effect in fracture healing. An unstable environment promotes 
chondrogenesis, while a stable environment promotes osteogenesis (52). The 
inflammatory response is also unique to fracture healing. Since bone fracture is an injury, 
it incites an inflammatory response. Inflammatory signals result in a local increase in 
macrophages, which in turn release factors and cytokines that promote healing. In 
contrast, bone formation occurs throughout the skeleton in a developing embryo, so 
systemic osteogenic signals prevail (52). Although tissue engineering strategies typically 
involve materials that mimic the structure and function of healed bone, recent progress in 
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developmental biology suggests that rapid regeneration may be achieved via scaffolds 
that simply trigger the "master switch" for regeneration (32). A growing body of 
evidence suggests that inflammatory signals are critical for the initiation of the fracture 
healing response. 
2.3. Role of Pro-inflammatory Molecules in Fracture Healing 
Pro-inflammatory cytokines are best known for their destructive effects on bone 
in a number of clinical contexts, and as such have not been extensively explored as 
potential initiators of regeneration in bone tissue engineering strategies. In biomaterials 
research, TNF-a, IL-l, and other pro-inflammatory cytokines are best known as 
mediators of the foreign body reaction, an inflammatory response that can cause both 
severe tissue damage and premature failure of implanted materials (53). Pro-
inflammatory molecules are also infamous for their catabolic effects on bone in patients 
with rheumatic diseases. High circulating levels of TNF -a and IL-l in arthritis patients 
are directly linked to joint and bone destruction (54). In a mouse model of arthritis, 
absence ofiL-1 due to a genetic mutation prevents bone and joint disease (55). Although 
it seems paradoxical, these same pro-inflammatory factors promote bone fracture healing. 
Unlike the unregulated, prolonged inflammation seen in severe foreign body 
reactions and bone pathologies like rheumatoid arthritis, inflammatory signaling in 
fracture healing is highly regulated and brief. Although inflammatory cells, mainly 
neutrophils and macrophages, are found at the site of an injury, their absence does not 
adversely affect tissue repair in mice (56). Recent studies in cell and developmental 
biology suggest that the pro-regenerative function of inflammatory signals is a 
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consequence of changes in the tissue microenvironment (e.g. expression of cell-surface 
receptors) triggered by injury. TNF-a, IL-l, and other inflammatory molecules are 
resilient molecules that readily diffuse through the extracellular matrix and are thus 
ideally suited for transmission of signals guiding regeneration. As discussed in this 
section, altered levels of TNF-a, IL-l, and other pro-inflammatory molecules have a 
major effect on the healing of bone fractures (57). 
2.3.1. Tumor Necrosis Factor (TNF-a) 
TNF -a and related molecules can either trigger cell death or promote cell survival 
depending on the specific cell-surface receptor they bind, the cell type, and the 
intracellular signaling cascade that is subsequently activated (58). In fracture healing, the 
expression of TNF-a and its receptors, TNFRl and TNFR2, follows a biphasic pattern. 
As shown in Figure 2.1, TNF-a concentration peaks 24 hours after bone injury in mouse 
models, returning to baseline levels within 72 hours. During this period, TNF -a is mainly 
expressed by macrophages and other inflammatory cells (38, 59). This brief TNF-a 
signaling is believed to induce the release of secondary signaling molecules and to exert a 
chemotactic effect, recruiting cells necessary for bone regeneration. TNF -a concentration 
rises again approximately two weeks later, during endochondral bone formation (see 
Figure 1). During this period, TNF-a is expressed by osteoblasts and other cells of 
mesenchymal origin, including hypertrophic chondrocytes undergoing endochondral 
bone formation (30, 59). Absence of TNF-a impairs fracture healing in mice, delaying 
endochondral bone formation by several weeks. However, TNF-a-deficient mice have 
normal skeletons, suggesting that TNF-a signaling is unique to post-natal fracture repair 
(1). 
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Figure 2.1: Expression of pro-inflammatory mediators after bone fracture. 
Schematic depicting the temporal pattern expression of three pro-inflammatory signals, 
tumor necrosis factor alpha (TNF-a), interleukin-1 (IL-l), and IL-6, after bone injury. 
The levels of each molecule are expressed as a percentage of the maximal level observed 
over the time period indicated. This graphic representation does not indicate 
concentrations of one molecule relative to another. Schematic is based on quantitative 
analysis of in vivo mRNA expression following bone injury (37, 59). 
Although the effects of TNF -a on bone have been studied for decades, it has only 
recently been recognized that this molecule can exert opposite effects depending on the 
context in which it is released (58). Stimulation of the molecular signaling pathway 
responsible for TNF -a production induces osteogenic differentiation of mesenchymal 
stem cells in vitro, while signals that suppress TNF -a release decrease osteogenic 
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differentiation (60). TNF-a regulates the differentiation and function of both osteoblasts 
and osteoclasts via TNFRl and TNFR2, the two cell-surface receptors for TNF-a (61). 
TNFRl is always present in bone tissue. In contrast, TNFR2 is only expressed following 
bone injury (59). In an in vitro culture system, TNF-a signaling promoted bone formation 
in cells from both normal and TNFRl-deficient mice. However, the opposite effect was 
observed with TNFR2-deficient cells, where TNF -a signaling stimulated osteoclast 
differentiation and bone resorption ( 62). Secondary signals arising from the activation of 
TNFR2 receptor likely mediate the pro-regenerative effects of TNF -a in fracture healing 
(59, 62). 
2.3.2. Interleukin-1 (IL-l) 
Although it acts through a distinct molecular signaling pathway, the effect of IL-l 
on bone largely overlaps with that ofTNF-a (61). Like TNF-a, IL-l expression follows a 
biphasic pattern. In a mouse model of fracture healing, its concentration rises 
immediately after bone fracture, peaking after 24 hours and returning to undetectable 
levels by 72 hours, as shown in Figure 1. The main source of IL-l during this 
inflammatory phase is macrophages (37, 59). IL-l triggers release of IL-6, 
prostaglandins, and other pro-inflammatory secondary signals (63). It also stimulates 
angiogenesis and promotes formation of the cartilaginous callus that stabilizes the 
fracture site (39). A second peak in IL-l expression occurs approximately three weeks 
following the injury (see Figure 1 ). During this period, IL-l is mainly expressed by 
osteoblasts and facilitates bone remodeling by stimulating proteases to degrade callus 
tissue (39, 59). 
The diverse functions of IL-l during fracture healing can be attributed to the 
differential expression of the two IL-l receptors, IL-lRI and IL-lRII. In a murine model 
of fracture healing, the expression of IL-lRII follows the same biphasic pattern as its 
ligand, IL-l. In contrast, IL-lRI is only detectable during the inflammatory phase (59). 
IL-lRI-deficient mice have decreased bone mass and two-fold increased levels of 
osteoclasts ( 64 ), which underscores the importance of this molecular signal in bone 
homeostasis. 
2.3.3. Interleukin-6 (IL-6) 
IL-6 is produced by osteoblasts, in response to stimulation by IL-l (39). In mouse 
models of bone regeneration, levels of IL-6 rise immediately after injury and return to 
baseline by the end of the first week (see Figure 1) (38). IL-6 regulates the differentiation 
of both osteoblasts and osteoclasts, and also promotes angiogenesis by stimulating release 
of VEGF (65). Unlike TNF-a and IL-l, IL-6 expression is limited to the inflammatory 
phase. Levels of IL-6 remain at baseline in the remodeling phase of fracture healing (38). 
Absence of IL-6 significantly delays the early stages of fracture healing, including 
mineralization and remodeling of the fracture callus. Two weeks after bone fracture, IL-
6-deficient mice have reduced mineralization and increased cartilage content at the 
fracture site; four weeks after the injury, fracture healing is comparable to that of IL-6-
replete mice (65). In human patients, IL-6 remains elevated for up to several months 
following fracture. Higher levels correlate with decreased load-bearing capability at 
injury site (66, 67). 
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2.3.4. Additional Cytokines 
The increasing recognition of the central role and unique function of pro-
inflammatory signals in bone regeneration has stimulated research on the effects of other 
interleukins. There is a growing amount of evidence that a large number of cytokines 
play an important role in bone regeneration. 
2.3.4.1. Interleukin-4 (IL-4) 
IL-4 is a so-called "inhibitory cytokine," a term used by immunologists to 
describe molecules that tend to counteract the pro-inflammatory effects of TNF -a and IL-
l (63). IL-4 targets both osteoclasts and osteoblasts, inhibiting in vivo bone remodeling. 
Genetically modified mice that overproduce IL-4 develop severe osteoporosis; their 
bones have reduced stiffness and a propensity for failure when subjected to mechanical 
loads (68). 
2.3.4.2. Interleukin-5 (IL-5) 
IL-5 has only recently been recognized as having a role in osteogenesis. A mouse 
model genetically engineered to express high levels of IL-5 developed ectopic 
ossification in the spleen. Splenic bone nodules were indistinguishable from normal bone 
by histology, exhibited osteoblast-specific gene expression, and had mineral content 
consistent with that of bone matrix (69). Additionally, bone formation was significantly 
increased in the long bones of these mice. When normal mice were transplanted with 
bone marrow from the transgenic mice, they developed identical pathology, including 
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formation of splenic bone nodules and increased cancellous bone formation in the long 
bones (69). 
2.3.4.3. Interleukin-12 and Interleukin-18 (IL-12 and IL-18) 
IL-12 inhibits in vitro osteoclast differentiation. This anti-resorptive effect is 
magnified when IL-18, which is produced by osteoblasts, is simultaneously administered 
to murine osteoclast progenitors in vitro (70). The mechanism of IL-12 and IL-18 
remains unclear. Their effect on osteoclast progenitors is indirect and involves increased 
production of IFN-y (71). Overproduction of IL-18 stimulates IFN-y production and 
suppresses IL-4 in vivo, resulting in cortical thinning and decreased bone volume in a 
mouse model (72). 
2.3.4.4. Interferon-y (IFN-y) 
IFN-y levels rise in response to bone injury and remain elevated throughout most 
of bone healing, returning to baseline late in the remodeling phase (38). Research on the 
mechanism of this cytokine has been complicated by its opposite effects on bone 
resorption in vitro and in vivo (63). IFN-y stimulates alkaline phosphatase activity in 
human osteoblasts (73), while suppressing the in vitro differentiation of osteoclasts (74). 
IFN-y-receptor deficient mice have increased osteoclast formation in the presence of 
bone inflammation, indicating that IFN-y has a protective, anti-resorptive effect (74). 
However, systemic administration of IFN-y to rats for eight days triggers severe 
osteopenia (75). IFN-y stimulates bone resorption in human patients with osteopetrosis, a 
disease associated with osteoclast dysfunction (63). 
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The effect of inflammatory cytokines on bone depends on the timing and context 
of their expression. A single cytokine can have both pro-regenerative and pro-resorptive 
effects on bone. Further research on the mechanism of these molecules will enable their 
incorporation into tissue engineering strategies to rationally control inflammation and 
induce regeneration. 
2.4. Effect of Drugs that Modulate the Inflammatory Response 
The number of studies documenting the effects of drugs that modulate the 
inflammatory response on fracture healing has grown rapidly within the past few years. 
This likely reflects increasing awareness amongst clinicians and pharmacologists of the 
key role of inflammatory signaling. However, these insights are not yet widely 
recognized in the field of tissue engineering, and thus few studies have attempted to 
integrate this knowledge into a bone tissue engineering strategy. Recent advances in 
molecular and cell biology have enabled researchers to specifically target bone tissue, 
avoiding potentially severe side effects, including systemic inflammation or, conversely, 
immunosuppression (76). This section summarizes the effects of pharmacologic 
modulation of the inflammatory response on bone regeneration in vivo, and the limited 
cases in which this knowledge has already been incorporated into tissue engineering 
strategies. 
2.4.1. Cytokine-Specific Agents 
Four inhibitory agents that specifically target pro-inflammatory molecules are 
currently used in human patients; infliximab (Remicade®), adalimumab (Humira®), and 
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etanercept (Enbrel®) are antibodies that block the function of TNF-a, while anakinra 
(Kineret®) blocks binding of IL-l to its receptor. These selective anti-cytokine therapies 
do not impair bone fracture healing in human patients, which likely reflects the low 
dosages used clinically, since higher dosages increase the risk of severe infections, 
particularly tuberculosis (77, 78). However, in an in vitro model of bone healing, addition 
of anti-TNF -a antibodies obliterated the dose-dependent increase in bone formation 
triggered by TNF-a (62). 
Stimulation of the signaling pathways activated by TNF -a, IL-l, and other pro-
inflammatory mediators also enhances fracture healing. A recent study indicates that the 
synthetic peptide TP508, which enhances in vivo bone regeneration in a variety of animal 
models, activates the same signaling pathways stimulated by TNF -a, IL-l, and other pro-
inflammatory cytokines during fracture healing (79). A single injection of TP508 into a 
femoral fracture increased the strength of the healed bone by over 30% in a rat model 
(80). Molecular analysis of this same model indicated that TP508 altered protein 
expression for 7 days, even though the half-life ofTP508 at the fracture site was less than 
12 hours. The differentially expressed proteins belonged to molecular signaling pathways 
that regulate osteoclasts and osteoblasts (79). Similar effects on bone healing in rabbits 
have been reported with controlled release of TP508 from PLGA microspheres and 
poly(propylene fumarate) scaffolds (81, 82). A recent placebo-controlled phase 1111 study 
indicates that TP508 significantly accelerates the healing rate of human diabetic foot 
ulcers (83). 
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2.4.2. Corticosteroids 
Numerous studies have indicated that corticosteroids suppress in vivo fracture 
healing in rodents and rabbits (84-86). However, corticosteroids are known to promote in 
vitro osteogenic differentiation of mesenchymal stem cells (3). A recent study reported 
that intramuscular injections of methylprednisolone improved in vivo osteogenesis in 
tissue engineering scaffolds subcutaneously implanted in New Zealand white rabbits. The 
scaffolds were seeded with autologous chondrocytes, and the authors suggest that 
corticosteroids stimulated the chondrocytes to undergo endochondral bone formation 
(87). In human patients, prolonged corticosteroid treatment is known to cause bone 
necrosis (88). In fact, corticosteroids are clinically used to reduce osteogenesis in patients 
with fibrodysplasia ossificans progressiva, a disease associated with excessive bone 
formation (89, 90). Further studies of the effect of these agents are necessary to establish 
their effects on the various phases of bone healing. 
2.4.3. Prostaglandins and Non-Steroidal Anti-inflammatory Drugs (NSAIDs) 
Prostaglandins are pro-inflammatory molecules that enhance bone regeneration by 
promoting angiogenesis and stimulating both osteoclasts and osteoblasts (91). The rate-
limiting step in their synthesis is catalyzed by the enzyme cyclooxygenase (COX), which 
exists in two forms, COX-1 and COX-2. COX-1 is present in normal bone, and triggers 
the production of low levels of prostaglandins. COX-2 expression is triggered by bone 
injury and results in high levels of prostaglandin synthesis (76, 92). Absence of COX-2, 
due to genetic mutation, impairs fracture healing in mice (93, 94). 
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Non-steroidal anti-inflammatory drugs (NSAIDs), the most common class of anti-
inflammatory medication, reduce inflammation by inhibiting prostaglandin synthesis. 
Numerous publications over the past three decades have reported that both non-selective 
NSAIDs, which target both COX-1 and COX-2, and selective COX-2 inhibitors (e.g. 
celecoxib) delay or inhibit in vivo fracture healing [recently reviewed by (76, 91)]. A 
recent study indicates that indomethacin, a non-selective NSAID, delays in vivo femoral 
fracture healing in rats, while celecoxib (Celebrex®) and rofecoxib (Vioxx~, both COX-
2 selective inhibitors, cause osseous nonunion (93). A significant increase in the 
proportion of nonunions, along with a significant decrease in fracture callus strength, is 
evident after just five days of celecoxib therapy (95). The effect of these drugs is limited 
to the initial period of fracture healing, corresponding to the inflammatory phase; giving 
celecoxib either prior to fracture or 14 days after fracture has no effect on fracture healing 
(95). The inhibitory effect of these drugs on fracture healing is reversible. Rats given 
valdecoxib (Bextra®), another COX-2 selective inhibitor, for 21 days following femur 
fracture had significantly increased incidence of osseous nonunion; two weeks after 
treatment was stopped, there were no differences between experimental and control 
groups (96). 
Clinical studies of human patients support the experimental findings in animal 
models. Use ofNSAIDs after long bone fracture significantly increases the risk of either 
delayed union or nonunion (97, 98). NSAIDs are consequently used to prevent 
heterotopic bone formation after hip surgery. Just 5-7 days of post-operative treatment 
with NSAIDs effectively prevents ectopic bone formation (99). As expected from these 
findings, in hip surgery patients with simultaneous long bone fractures, NSAIDs 
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significantly increase the risk of nonunion at long bone fracture sites. Incidence of 
nonunion increases by as much as four-fold, suggesting that these patients should be 
treated with alternative methods to suppress ectopic bone formation (1 00). 
2.4.4. Selective Prostaglandin Agonists 
Increased bone formation is a known side effect of prostaglandins, which are 
commonly used to maintain a patent ductus arteriosus in infants with congenital heart 
disease (101). However, they have not been pursued as a therapeutic agent to promote 
fracture healing because of the risk of severe side effects, including systemic 
inflammation (76). Recent studies indicate that there are several prostaglandin receptors, 
each with a distinct tissue distribution and secondary signaling cascade. The main effects 
on bone are exerted via the EP2 and EP4 receptors (91). Selective EP2 and EP4 receptor 
ligands may be used for bone repair, while avoiding systemic side effects. A recent study 
indicates selective EP2 receptor agonists stimulate in vivo fracture healing in rodents and 
dogs (1 02). For the dog studies, EP2 agonists encapsulated in a PLGA carrier enhanced 
in vivo healing of critical-size radial defects and tibial bone defects (1 02). A similar effect 
has been reported for EP4 agonists in rat femoral defects (103). 
2.5. Conclusions 
The impact of TNF-a, IL-l, and other pro-inflammatory signals on bone 
regeneration underscores the importance of incorporating rational control of 
inflammation into the design of tissue engineering strategies. Modulation of the 
inflammatory response is a new direction in the field of tissue engineering. To our 
knowledge, few studies have attempted to integrate inflammatory modulation into tissue 
engineering strategies to enhance bone regeneration. Novel strategies that exploit 
inflammatory signals have the potential to induce greater regeneration than current 
systems, which only deliver growth factors. In bone tissue engineering, a better 
combination of renewal signals will decrease the required dose of factors like BMP-2, 
limiting their release to the injury site and thus minimizing ectopic effects likely in 
current systems. Rational control of the inflammatory response will provide a powerful 
strategy to induce healing of engineered tissue. 
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Chapter 3 
Background: Harnessing and Modulating 
Inflammation in Strategies for Bone 
Regeneration3 
Abstract: Inflammation is an immediate response that plays a critical role in healing 
after fracture or injury to bone. However, in certain clinical contexts, such as in 
inflammatory diseases or in response to the implantation of a biomedical device, the 
inflammatory response may become chronic and result in destructive catabolic effects on 
the bone tissue. Since our previous review three years ago 4, which identified 
3 This chapter will be published as: Mountziaris PM, Spicer PP, Kasper FK, Mikos AG. Harnessing and 
Modulating Inflammation in Strategies for Bone Regeneration. Tissue Engineering Part B: Reviews 2011; 
In Press (available online ahead of print: doi:l0.1089/ten.teb.2011.0182). 
4 Included in the preceding chapter of this thesis. 
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inflammatory signals critical for bone regeneration and described the inhibitory effects of 
anti-inflammatory agents on bone healing, a multitude of studies have been published 
exploring various aspects of this emerging field.· In this review, we distinguish between 
regenerative and damaging inflammatory processes in bone, update our discussion of the 
effects of anti-inflammatory agents on bone healing, summarize recent in vitro and in 
vivo studies demonstrating how inflammation can be modulated to stimulate bone 
regeneration, and identify key future directions in the field. 
3.1. Introduction 
Inflammation is a highly regulated biological response that plays an immediate 
and crucial role in promoting regeneration following bone fracture or injury (104, 105). 
However, in certain clinical contexts, such as in inflammatory diseases or severe foreign 
body reactions to implanted materials, the normal inflammatory response fails to resolve, 
resulting in chronic inflammation that has destructive effects on bone tissue. A 
tremendous amount of effort has been invested in developing pharmacologic agents to 
disable this uncontrolled inflammatory signaling and thus prevent bone damage (106, 
1 07). In the process, a growing body of evidence has emerged that indicates that a 
complex balance exists between bone tissue and the immune system, which is responsible 
for the inflammatory response, and that obliterating inflammation also has damaging 
effects on bone (104, 106, 108). We previously published a review (104) that introduced 
this information to the bone tissue engineering community by identifying inflammatory 
signals critical for bone regeneration and describing the inhibitory effects of anti-
inflammatory agents on bone healing. Since our previous review, a multitude of studies 
have been published exploring new strategies to harness and modulate inflammation to 
facilitate bone regeneration. 
The objectives of this review are to: (1) distinguish between regenerative and 
damaging inflammatory processes in bone; (2) identify anti-inflammatory agents that 
inhibit bone healing; (3) summarize recent in vitro and in vivo studies to demonstrate how 
inflammation can be modulated to stimulate bone regeneration; and (4) combine this 
information to identify key future directions in the field. 
3.2. Regenerative vs. Damaging Inflammatory Processes in Bone 
3.2.1. Inflammatory signaling during bone regeneration 
Inflammation is an immediate response to bone injury, and a growing body of 
evidence indicates that the signaling cascades initiated during the week-long acute 
inflammatory response play a critical role in priming bone regeneration (1 04, 105, 1 08). 
Bone fracture stimulates expression of several dozen inflammatory cytokines, including 
interleukin-la (IL-la), IL-l~, IL-6, IL-18, and tumor necrosis factor alpha (TNF-a) (30, 
37, 59). In murine models, TNF-a, IL-la, IL-l~, and IL-6 signaling peaks 24h following 
bone injury and returns to baseline levels after a few days (37, 59). Together with a 
variety of growth factors, including proteins from the transforming growth factor beta 
(TGF -~) and bone morphogenetic protein (BMP) families, fracture-induced inflammatory 
mediators recruit inflammatory cells, promote angiogenesis, and guide mesenchymal 
stem cell (MSC) differentiation (30, 37, 59). Several cytokines, including TNF-a, IL-6, 
and stromal cell-derived factor-1 (SDF-1), have been shown to directly impact the in vivo 
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migration of MSCs (1 09-112). Levels of most inflammatory mediators return to baseline 
following the week-long acute inflammatory phase (30, 37, 59). 
Fracture healing involves overlapping phases of inflammation, renewal, and 
remodeling. During the renewal phase, the fracture site is stabilized by a cartilaginous 
callus, which then calcifies and undergoes endochondral bone formation. At this point, 
the remodeling phase begins. Levels of TNF -a and several other cytokines rise for a 
second time as the mineralized fracture callus is remodeled into lamellar bone by the 
renewing and resorptive actions of osteoblasts and osteoclasts, respectively (37, 39, 59, 
104). In vivo studies have identified cytokines from both the inflammatory and 
remodeling phases that are critical for bone regeneration. For instance, mice lacking 
either IL-6 or TNF -a have severely impaired fracture healing, with bone formation being 
delayed by several weeks (1, 65). Emerging strategies to harness this signaling and use it 
to stimulate bone regeneration are discussed in a separate section of this review. 
3.2.2. Role of inflammatory cells in bone regeneration 
Although inflammatory cells, mainly neutrophils and macrophages, are 
immediately recruited to the injury site and release a cascade of cytokines and growth 
factors, in vivo studies have not yet identified a crucial inflammatory cell type for fracture 
healing. Inflammatory cells are primarily present at the fracture site during the initial 
week-long inflammatory phase ofbone healing (105, 113). Within 3-7 days of injury, and 
continuing during the subsequent renewal and remodeling phases of healing, native bone 
cells in the regenerating fracture callus, mainly osteoblasts and chondrocytes, are the 
primary source of inflammatory cytokines such as TNF-a (59). This overlapping 
inflammatory signaling by native bone cells may explain the normal bone healing seen in 
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the absence of inflammatory cells. For instance, absence of neutrophils and macrophages 
does not adversely affect in vivo tissue repair (56). Absence of lymphocytes significantly 
accelerates in vivo fracture healing and remodeling, resulting in a mineralized fracture 
callus with superior biomechanical properties (114, 115). In a unique chimeric animal 
model, transplantation of inflammatory cells from aged mice with impaired bone 
regeneration into otherwise healthy juvenile mice did not affect in vivo fracture healing. 
However, in the inverse case, consisting of a middle-aged mouse with inflammatory cells 
derived from a juvenile mouse, fracture callus healing and remodeling were accelerated 
(116). It is possible that the beneficial effect of acute inflammation following bone injury 
may not be attributable to a particular cell type, but the relative proportions of the cells 
recruited to the injury site. A recent study in a sheep model indicated that the composition 
of the injury-induced inflammatory infiltrate is tissue-specific (113). For instance, 1h 
after injury, a bone fracture hematoma contained fewer neutrophils than a hematoma 
taken from a muscle injury site. However, by 4h after injury, this difference was no 
longer apparent, and the relative proportions of neutrophils, macrophages, and 
lymphocytes at the fracture site were identical to those seen in circulating blood (113). 
Any variation in the number and type of inflammatory cells, even for just a few hours, 
directly affects the balance between bone tissue and the immune system by altering the 
local concentration of growth factors and inflammatory cytokines that regulate bone 
healing. 
3.2.3. Aberrant inflammation results in bone damage 
The normal inflammatory response can be disrupted by many factors, including 
massive trauma and inflammatory diseases (1 06, 1 07). Aberrant inflammatory signaling 
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has been implicated as a significant factor in bone injuries that fail to heal. Osteoblasts 
taken from human patients with fracture nonunion had anomalous expression of 281 
genes, including sets of genes that regulate growth factor activity, osteogenesis, 
angiogenesis, cytokine activity, and the inflammatory response (117). Similar results 
were seen in an animal model of delayed osseous union; at several timepoints following 
bone injury, the tissue from the nonunion site had reduced expression of several growth 
factors, including BMP-2, BMP-4, BMP-7, and TGF-~1, as well as the cytokine TNF-a 
(118). These findings underscore the importance of regulated acute inflammatory 
signaling in priming bone regeneration. 
The impact of inflammatory diseases on bone is not a direct effect of 
inflammatory cells. In a model of rheumatoid arthritis, mice with reduced osteoclast 
numbers were protected from bone damage, despite the infiltration of high numbers of 
inflammatory cells into the bone (119). However, osteoclast-deficient mice were not 
protected from other destructive effects of inflammatory arthritis, like cartilage damage 
(119). 
When acute inflammation fails to resolve, e.g., due to the presence of an 
underlying inflammatory disease like rheumatoid arthritis, the resulting prolonged, 
unregulated inflammatory signaling has damaging effects on bone. For example, although 
TNF -a and IL-6 have been shown to be critical for in vivo bone regeneration in murine 
models (1, 65), chronic exposure to high levels of these cytokines has damaging effects 
on bone. In murine models, prolonged, systemic exposure to high levels of TNF -a 
triggers tissue damage and symptoms resembling those of rheumatoid arthritis, including 
chronic inflammation, decreased bone volume, and reduced bone mechanical strength 
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(120). In a recent study of a mouse model of type 1 (i.e., autoimmune) diabetes, impaired 
fracture healing was attributed to excessive callus remodeling triggered by elevated 
expression of several inflammatory mediators, including TNF-a (121). Systemic 
treatment with a TNF-a inhibitor starting 10 days after bone fracture significantly 
improved fracture healing in the diabetic mice (121). Abnormally elevated levels ofiL-6 
also have damaging effects on bone. In human patients, abnormally high serum IL-6 
levels in the days and even months following bone fracture correlate with decreased load-
bearing capability of the injured bone (66, 67). In a recent study, serum from human 
patients with polyarticular juvenile idiopathic arthritis, an autoimmune disorder that 
causes chronic joint inflammation, significantly suppressed in vitro osteogenesis of 
human osteoblasts, as determined by comparing their alkaline phosphatase (ALP) 
expression, osteocalcin protein level, and calcified matrix deposition to that of osteoblasts 
cultured in serum from healthy controls (122). Analysis of the arthritic serum indicated 
that IL-6 was the only cytokine that was abnormally elevated (122). This highlights the 
difference between the highly regulated acute inflammation that occurs during bone 
fracture healing, compared to the unregulated chronic inflammation seen in arthritis and 
autoimmune disease. 
3.3. Effects of Anti-Inflammatory Drugs on Bone Healing 
A tremendous amount of effort has been invested in developing pharmacologic 
agents to disable uncontrolled inflammatory signaling and thus prevent bone damage in 
patients with inflammatory diseases (1 06, 1 07). A wide variety of anti-inflammatory 
medications are available to treat ailments ranging from musculoskeletal pain to chronic 
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inflammation associated with autoimmune disease. However, therapeutic strategies have 
been complicated by the complex balance that exists between bone and the immune 
system, which is responsible for the inflammatory response; a growing number of studies 
indicate that anti-inflammatory medications have predominantly negative effects on bone 
healing (76, 104). In most cases, instead of recommending the discontinuation of anti-
inflammatory medications, current clinical guidelines instruct physicians to assess the 
risk/benefit ratio for each individual patient (123). For researchers, considering the 
effects of the anti-inflammatory medications discussed in this section will aid in the 
design of more effective bone regeneration strategies. 
3.3.1. Corticosteroids 
Although corticosteroids are commonly used in vitro to induce osteogenic 
differentiation of mesenchymal stem cells (MSCs) (3), they are known to have negative 
effects on in vivo bone homeostasis and regeneration. In human patients taking 
corticosteroids, e.g., to treat the chronic inflammation associated with rheumatoid 
arthritis, monitoring for adverse effects on bone, including reduced bone density and 
bone necrosis, is part of standard clinical practice (124, 125). Numerous studies have 
shown that corticosteroids suppress in vivo fracture healing in rodents and rabbits by 
reducing osteogenesis, angiogenesis, and mechanical strength at the fracture site (84-86, 
126, 127). Studies of genetically altered mice have demonstrated that baseline native 
corticosteroid signaling in osteoblasts is necessary for bone morphogenesis, but not for 
bone regeneration (128). Mice lacking corticosteroid signaling in osteoblasts had normal 
bone healing following tibial fracture (128). In recognition of their negative effects on 
bone, corticosteroids are not prescribed to human patients with bone injuries (76). In fact, 
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corticosteroids are a common therapeutic agent for human patients with fibrodysplasia 
ossificans progressiva, a disease associated with excessive bone formation (129). 
Although long-term treatment with corticosteroids inhibits bone regeneration, the 
effects of short-term in vivo exposure remain unclear. Recent tissue engineering studies 
have reported a wide variety of effects of short-term corticosteroid exposure, ranging 
from no effect to substantial, beneficial effects on bone regeneration. Two recent studies 
have reported that 3D poly(DL-lactic-co-glycolic acid) (PLGA)-based scaffolds 
delivering dexamethasone stimulated in vivo bone regeneration in critical-size defects 
after 4-8 weeks, compared to empty defects (130, 131 ). However, neither study 
demonstrated a clear benefit of dexamethasone delivery, since equivalent bone 
regeneration was seen with dexamethasone-free scaffolds in each case (130, 131). The 
effect on in vivo osteogenesis may depend on the method and temporal pattern of 
corticosteroid delivery. In a study of rat MSC-seeded titanium fiber meshes implanted in 
critical-size rat cranial defects for 4 weeks, MSC preculture in media supplemented with 
dexamethasone for 4 days resulted in superior bone regeneration compared to MSCs 
cultured without dexamethasone. However, exposure to dexamethasone for 16 days 
resulted in much less bone formation than seen with untreated MSCs (132). In another 
study, MSCs precultured with dexamethasone for 1 week and seeded onto hydroxyapatite 
scaffolds resulted in increased ectopic bone formation in a rat subcutaneous implantation 
model; greater bone formation occurred when dexamethasone was supplied through a 
nanoparticle-based delivery system added to the preculture medium rather than as a free 
drug in solution (133). In a rabbit model, systemic injection of the corticosteroid 
methylprednisolone increased ectopic bone formation in subcutaneously implanted 
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chondrocyte-seeded PLGA scaffolds compared to rabbits not treated with corticosteroids 
(87). 
In contrast to the diverse effects of corticosteroids in these animal models a 
' 
recent case study reported that implanting a dexamethasone-loaded gelatin scaffold in 
human patients with osseous nonunion stimulated bone regeneration (134). Autologous 
bone marrow and bone fragments were collected from the non-injured femur of each 
patient and incubated in vitro in a high concentration (10"5 M) of dexamethasone for 1-
2h. The liquid portion of the mixture was then absorbed into a gelatin scaffold, which 
was packed into the site of osseous nonunion, and then surrounded by the 
dexamethasone-treated bone fragments. After 6-8 months, only 1113 patients had 
persistent nonunion, and 6/13 had achieved complete union (134). Additional research is 
necessary to establish the role of corticosteroids in the various phases of bone 
regeneration and better understand the mechanism of the diverse effects seen in humans 
and animals with bone injuries. 
3.3.2. Cytokine-specific antagonists 
To avoid the negative effects of non-specific agents like corticosteroids, the 
chronic inflammation seen in auto-immune diseases is increasingly being treated with 
medications that specifically target a portion of the immune system. For instance, 
rheumatoid arthritis is treated using monoclonal antibodies and other synthetic biologic 
agents that target 1NF -a, IL-l, and IL-6. These cytokine-specific inhibitors are a new 
class of medications, having only been approved for use in humans within the past 10 
years (77, 78). Seven agents that antagonize specific cytokines are currently approved for 
use in human patients: infliximab, adalimumab, etanercept, golimumab, and 
certolizumab-pegol inhibit 1NF-a, while anakinra and tocilizumab antagonize IL-l and 
IL-6, respectively (135). Only a small number of studies have reported the effects of 
these agents on bone healing, and the results have been inconclusive. Most studies have 
focused on the oldest cytokine-specific antagonists, the 1NF -a blockers in:fliximab, 
adalimumab, and etanercept. Several studies of human patients undergoing orthopedic 
surgery have shown no significant impact of 1NF -a antagonists on the incidence of 
adverse events or wound healing complications (136, 137). In contrast, other studies have 
shown that patients treated with 1NF-a antagonists had a statistically significant 
increased risk of orthopedic surgical site infection and other complications (138, 139). 
Since absence of 1NF -a has been shown to be detrimental to bone regeneration in an 
animal model (1), the inconsistent inhibition of bone healing seen in human patients is 
believed to stem from the very low doses of these medications that are prescribed, since 
higher doses suppress the immune system and increase the risk of severe infections like 
tuberculosis (77, 135). However, the specific mechanism of each agent may also play a 
role. A recent in vitro study of human osteoblasts exposed to therapeutic doses of two 
1NF-a antagonists indicated that infliximab had a negative effect on osteoblast 
proliferation, while etanercept had no effect (140). 
3.3.3. Non-steroidal anti-inflammatory drugs (NSAIDs) 
Non-steroidal anti-inflammatory drugs (NSAIDs), a large group of medications 
ranging from over-the-counter pain relievers like ibuprofen to prescription-only anti-
inflammatories like celecoxib (Celebrex®), are the most widely studied anti-
inflammatory medications in bone biology. The detrimental effects of various NSAIDs 
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on bone regeneration have been documented in both human patients and animal models 
for several decades (recently reviewed by (141, 142)). 
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NSAIDs target the cyclooxygenase (COX) enzymes, which catalyze the rate-
limiting step of prostaglandin synthesis. There are two forms of COX; COX-1 is 
constitutively expressed in bone and results in low levels of prostaglandin synthesis, 
while COX-2 is triggered by bone injury and results in high levels of prostaglandin 
production (76). Recent studies have identified COX-2 as a critical enzyme in bone 
regeneration. In mouse models, absence of COX -1 due to genetic mutation did not affect 
bone regeneration, while absence of COX-2 impaired fracture healing and increased the 
risk of osseous nonunion (93, 94). Consistent with these results, studies in rodent and 
rabbit models have shown that selective COX-2 inhibitors cause greater reductions in 
bone mineral density and mechanical properties at the injury site than nonselective 
NSAIDs, which inhibit both COX-1 and COX-2 (96, 143, 144). 
The detrimental effects of COX-2 inhibition are most profound in the initial 
inflammatory phase of fracture healing. In rat models, administration of COX-2 
inhibitors for 5-7 days immediately after bone injury resulted in measurable effects 4-8 
weeks later. COX-2 inhibition significantly reduced fracture callus mechanical strength 
and bone mineral density, and also increased the incidence of osseous nonunion (95, 143, 
145). However, treating the rats with a COX-2 inhibitor either prior to bone fracture or 
starting 14 days after fracture had no effect on bone healing (95). Systemic COX-2 has 
been shown to be critical for in vivo bone regeneration; local delivery of COX-2 within a 
bone graft in mice lacking COX-2 could not compensate for the detrimental effects on 
bone healing (146). 
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Studies ofNSAID effects in human patients with bone injuries support the results 
of these animal studies. NSAIDs have been shown to significantly increase the risk of 
delayed union or nonunion following long bone injury (97, 98). As with corticosteroids, 
NSAIDs are consequently used to prevent and treat ectopic or excessive bone formation 
in human patients (99, 129, 147). For instance, NSAIDs are used to prevent heterotopic 
bone formation after hip surgery, with as little as 5-7 days of postoperative NSAID 
administration being sufficient to inhibit ectopic bone formation (99). However, in hip 
surgery patients who also have long bone fractures, NSAID use increases the risk of 
nonunion in the long bone by fourfold (1 00). This underscores the fact that excessively 
suppressing inflammation can disrupt normal bone healing. In light of these findings, 
current clinical guidelines recommend that NSAIDs be avoided for the two weeks 
following a bone fracture, particularly in patients with a higher risk of osseous nonunion 
(123, 141). 
3.4. Harnessing Inflammation to Stimulate Bone Regeneration 
Stimulation of bone inflammation has not been extensively studied in vivo due to 
the risk of systemic inflammation and subsequent tissue damage. However, increasing 
awareness of the importance of certain inflammatory signals in priming bone 
regeneration has led to several recent in vitro and even some in vivo studies. 
3.4.1. Prostaglandin E2 Receptor Agonists 
Among the various prostaglandin types, prostaglandin E2 has been shown to have 
the most profound effects on bone homeostasis. Injury-induced increased prostaglandin 
E2 production is critical for bone regeneration (148, 149). The specific bone cell types 
that respond to prostaglandin E2 remain unclear, although both osteoclast progenitors and 
mature osteoblasts have been implicated based on in vitro studies (144, 150). In vivo, 
signaling via the prostaglandin E2 type 1 (EP1) receptor has been shown to negatively 
regulate bone regeneration, while signaling via the EP2 and EP4 receptors stimulates 
bone formation (150). Synthetic molecules selectively targeting these latter receptors 
have consequently been used in bone regeneration strategies. Local injection of selective 
EP2 agonists improved in vivo fracture healing in rodent models (102, 151). In addition, 
implantation of a PLGA matrix encapsulating an EP2 agonist into a critical-size canine 
ulnar defect stimulated osseous union after 24 weeks (1 02). Delivery of selective EP4 
receptor agonists has also shown promising results. In rodent models, both local and 
systemic delivery of EP4 selective agonists stimulated in vivo osteogenesis and 
angiogenesis, resulting in accelerated fracture healing (1 03, 151 ). Dual delivery of BMP-
2 and an EP4 agonist from a PEG-based hydrogel stimulated bone formation in a critical-
size murine cranial defect model; bone regeneration was greater with dual delivery than 
with delivery of either agent alone (152). 
3.4.2. Leukotriene Antagonists 
Modulation of leukotriene signaling is a very new bone regeneration strategy 
(153). Leukotrienes are a group of inflammatory signaling molecules that have the same 
metabolic precursor, arachidonic acid, as prostaglandins. However, unlike COX-2, which 
is the rate limiting enzyme in prostaglandin synthesis and has been shown to play a 
critical role in bone regeneration, the key enzyme in leukotriene synthesis, 5-
lipoxygenase, is detrimental to fracture healing (153). One proposed mechanism for the 
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impaired fracture healing seen with COX-2 inhibition is increased arachidonic acid 
availability to 5-lipoxygenase (153), which results in abnormally elevated leukotriene 
levels at the fracture site (154). In a rat model, administration of a 5-lipoxygenase 
inhibitor for 3 weeks following femoral fracture resulted in faster fracture bridging and 
superior mechanical properties at the fracture site compared to untreated rats (155). 
Similar accelerated fracture healing was reported in mice genetically altered to lack 5-
lipoxygenase (154, 155). Two clinically available leukotriene antagonists, montelukast 
sodium (Singulair®), a cysteinyl leukotriene type-1 receptor antagonist, and zileuton 
(Zyflo®), a 5-lipoxygenase inhibitor, also have beneficial effects on femoral fracture 
healing in a mouse model (156). Both agents are currently approved by the United States 
Food and Drug Administration (FDA) for the treatment of inflammatory airway diseases 
such as asthma. Systemic administration of either leukotriene antagonist significantly 
accelerated bone regeneration compared to fracture healing in untreated controls (156). 
Further mechanistic analysis indicated that the leukotriene antagonists enhanced fracture 
healing by directly affecting chondrocyte activity within the fracture callus (156). These 
recent results highlight the promise of modulating leukotriene synthesis as a new strategy 
to stimulate bone regeneration. 
3.4.3. Modulating Cytokine Activity 
Direct modulation of cytokine activity to promote bone regeneration is a new 
strategy that remains largely at the cell culture testing stage, though a few in vivo studies 
have been recently published. The most commonly studied cytokines are TNF -a, IL-l, 
and IL-6. 
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3.4.3.1. TNF -a 
Since the mechanism of 1NF -a in bone regeneration remains unknown, studies to 
date have been mainly conducted in vitro. These studies have revealed weaknesses in the 
typical in vitro culture conditions used to study MSC osteogenic differentiation and 
necessitated changes to standard cell culture protocols. 1NF -a does not affect in vivo 
embryonic skeletal development (1), but plays a critical role in bone regeneration. Mice 
lacking 1NF-a have severely impaired fracture healing, with bone formation being 
delayed by several weeks (1, 2). Exposure to 1NF-a significantly affects the in vitro 
protein expression, proliferation, and migration of undifferentiated human MSCs, but has 
not been reported to induce differentiation (111, 157). Thus, in order to study the effects 
of 1NF-a on osteogenically differentiating MSCs, supplements must be added to induce 
MSC osteogenic differentiation. Studies of the effects of 1NF -a on osteogenic 
differentiation have been complicated by the fact that two supplements typically used to 
stimulate in vitro MSC osteogenic differentiation, dexamethasone and ascorbic acid, 
antagonize 1NF-a signaling (14, 62, 158). While commonly used in in vitro MSC 
cultures, dexamethasone, an anti-inflammatory corticosteroid, is not present in the in vivo 
bone fracture environment (104). Additionally, as discussed above, corticosteroids have 
been implicated in impaired bone fracture healing. One strategy to overcome this 
limitation and create a more realistic in vitro model of the fracture healing environment 
has been to preculture MSCs in osteogenic medium to trigger differentiation and then use 
medium without dexamethasone to study the effects of 1NF-a (14). In the absence of 
dexamethasone, treatment of osteoprogenitors with 1NF -a resulted in dose-dependent 
increases in ALP activity and mineralized matrix deposition, which are, respectively, 
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early and late markers of osteogenesis (14, 112, 159-161). In contrast, when added to 
dexamethasone-containing osteogenic medium, TNF -a had the opposite effect on MSCs 
(162, 163). The pro-regenerative effects of TNF-a seen in dexamethasone-free in vitro 
MSC cultures were recently confirmed in vivo through repeated injections of TNF -a into 
a fracture healing model. Daily local injections of TNF -a during the first two days after 
injury resulted in significantly increased fracture callus mineralization four weeks later 
(112). These findings for TNF-a emphasize the importance of developing clinically 
realistic in vitro culture models to improve the predictions of the in vivo effects of various 
cytokines. 
3.4.3.2. IL-l 
Unlike TNF-a, which does not affect skeletal development but is required for 
normal bone regeneration, absence of IL-l does not affect in vivo fracture healing (164). 
However, mice lacking IL-Ia and/or IL-lp, the two forms of IL-l, have significantly 
higher bone mineral density and femoral bone mass than normal mice, which has been 
attributed to impaired osteoclast development (165). In vitro studies of the effects of IL-
Ia and IL-lP on osteogenically differentiating MSCs have shown that these cytokines 
have similar effects as TNF-a (160, 162, 166). MSCs precultured to induce osteogenic 
differentiation and subsequently exposed to IL-lP (in dexamethasone-free medium) had 
significant dose-dependent increases in early and late markers of osteogenic 
differentiation (160), while simultaneous exposure to IL-lP and dexamethasone had the 
opposite effect (162). Simultaneous delivery of IL-l p and TNF -a had synergistic effects 
on in vitro MSC deposition of mineralized matrix (160). A recent study reported that 
daily local IL-l p injections during the first 3 days after bone fracture resulted in slightly 
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accelerated in vivo bone regeneration(164). When compared to the results of in vitro 
studies, this fmding once again emphasizes the need to deliver cytokines to MSCs under 
culture conditions simulating the in vivo fracture healing environment (e.g., no 
dexamethasone) in order to effectively predict in vivo results. 
3.4.3.3. IL-6 
IL-6 is required for both normal skeletal development and for bone regeneration. 
Mice lacking IL-6 have reduced bone mineral density and also have impaired fracture 
healing (65). In vitro studies of osteogenically differentiating cells have indicated that 
exposure to IL-6 for 3-6 days increases gene expression of osteogenic markers RUNX2 
and osteocalcin (167). In an in vivo fracture healing model, repeated local injections of 
parathyroid hormone fragments and IL-6 in the first two weeks after injury significantly 
increased fracture callus mechanical strength and accelerated osseous union (168). 
However, this treatment reduced the mechanical strength of non-injured bones, which 
was attributed to a systemic effect of the injected agents (168). This underscores the need 
for controlled release systems to provide targeted cytokine delivery to the site of bone 
injury. 
3.4.3.4. IL-4 
Although abnormally elevated IL-4 levels have long been known to inhibit in vivo 
bone remodeling and result in extremely weak, osteoporotic bones ( 68), absence of this 
cytokine due to genetic mutation was recently shown to have no effect on in vivo fracture 
healing (169). However, in a study of in vivo ectopic bone formation stimulated by 
implantation of xenogeneic demineralized bone matrix, absence of IL-4 and IL-13 
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reduced angiogenesis (169), a finding that may have implications for the development of 
bone tissue engineering strategies. 
3.4.3.5. Interferon-y 
Many studies of the effects of IFN -y on bone regeneration have focused on signal 
transducer and activator of transcription 1 (ST AT1 ), an intracellular signal that is a 
component of the IFN-y pathway. Absence of IFN-y signaling, due to absence of either 
STAT1 or the IFN-y receptor, increases the number of osteoclasts in bone in vivo, but 
also increases bone mass (170, 171). Absence of STAT1 also accelerates in vivo fracture 
healing and subsequent bone remodeling (171). Gelatin scaffolds loaded with 
fludarabine, a STAT1 inhibitor, stimulated in vivo ectopic bone formation when 
implanted subcutaneously in a mouse model. Dual delivery of BMP-2 and fludarabine 
revealed an additive effect of the two agents on in vivo ectopic bone formation (171). 
3.4.3.6. Stromal cell-derived factor-1 (SDF-1) 
SDF-1 is a new target in bone regeneration strategies. In animal models with 
reduced SDF-1 signaling, new bone formation two weeks after injury was 60-80% less 
than normal (109). In another study, porous PLGA scaffolds loaded with SDF-1 triggered 
MSC chemotaxis both in vitro and in vivo, resulting in MSC migration toward, and 
subsequent attachment to, the scaffold (110). SDF-1 delivery from subcutaneously 
implanted PLGA scaffolds significantly reduced in vivo fibrotic encapsulation and 
inflammatory cell accumulation near the scaffold (110), demonstrating the potential of 
this cytokine as a component of future immunomodulatory strategies to prevent foreign 
body reactions to biomedical implants. 
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3.4.3. 7. TP508 
TP508 (rusalatide acetate; Chrysalin®) is a synthetic peptide that stimulates the 
same signaling pathways activated by cytokines like TNF -a and IL-l (79). This peptide 
has been shown to be a very potent stimulator of in vivo bone regeneration, with a single 
injection into a rat femoral fracture increasing the strength of the healed bone by over 
30% (80). In rabbit models, TP508 has been shown to stimulate bone regeneration of 
critical-sized defects when incorporated into a PLGA microparticle-based controlled 
release system (81, 82). However, in a recent Phase III clinical trial of this agent, a single 
injection of TP508 into the site of a radius fracture failed to significantly improve (vs. 
placebo) the primary measure of success, which was the total time that the fracture 
required immobilization (172). However, further analysis revealed that in a subset of the 
clinical trial participants, i.e., female patients with osteopenia, TP508 was successful; it 
significantly reduced the amount of time that the fractures required immobilization, and 
also accelerated fracture healing (172). Further studies are needed to clarify the efficacy 
ofTP508 in patients with impaired bone regeneration capacity. 
3.4.4. Modulating Inflammatory Cell Activity 
Another emerging strategy is to directly target and modulate inflammatory cell 
function in bone. Small molecule inhibitors of cathepsin K, an enzyme specific to 
osteoclasts and other bone cells of the monocyte lineage, effectively reduced in vivo bone 
resorption and uncontrolled joint inflammation in a rat model of rheumatoid arthritis 
(173). Although the inherent immunomodulatory properties of MSCs have been 
recognized for approximately a decade, clinical strategies utilizing these cells have 
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focused on systemic injection of culture-expanded MSCs to treat immune diseases (174). 
A recent study indicates a strategy through which native MSC function can be modulated 
via local delivery of cytokines. MSCs exposed to IFN -y and either 1NF -a, IL-l a, or IL-f3 
have been shown to secrete factors that suppress T lymphocyte function in vitro (175). 
The MSCs also recruited additional T lymphocytes to the area, which were then also 
inactivated (175). 
3.5. Concluding Points 
Harnessing and modulating inflammatory signaling is a promising new strategy 
for bone regeneration. Since our previous review (104) three years ago, which introduced 
this topic to the bone tissue engineering community by identifying key inflammatory 
cytokines that prime bone regeneration and describing the inhibitory effects of anti-
inflammatory agents on bone healing, a multitude of in vitro and in vivo studies have 
focused on this topic. These studies have provided crucial information, as well as 
identified important questions to be answered in future work. 
The initial week-long inflammatory phase of fracture healing is characterized by 
the influx of inflammatory cells, i.e., neutrophils, lymphocytes, and macrophages, and the 
release of a variety of cytokines and growth factors. However, the mechanism by which 
these complex signaling cascades trigger scar-less bone regeneration remains unknown. 
Several cytokines, including 1NF -a and IL-6, have been shown to play a critical role in 
bone healing and have even been successfully harnessed to trigger regeneration in animal 
models of massive bone trauma. Although they are the primary source of inflammatory 
cytokines immediately after bone injury, no particular inflammatory cell type has been 
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identified as critical for bone regeneration. In fact, lymphocytes have been shown to 
impair bone healing, suggesting that the native bone cells are the most promising targets 
for rational control of bone inflammation. 
Engineering strategies to rationally control inflammatory signaling are necessary 
because of the complex balance that exists between bone tissue and the immune system, 
which is responsible for the inflammatory response. Precise spatial and temporal control 
is necessary when delivering cytokines because both prolonging and obliterating this 
signaling impairs bone healing. For instance, complete absence of TNF-a delays 
regeneration, while prolonged exposure to high levels of this cytokine stimulates bone 
destruction. 
A tremendous amount of effort has been invested in developing pharmacologic 
agents to treat uncontrolled, chronic inflammation and prevent bone damage. In the case 
of non-steroidal anti-inflammatory drugs (NSAIDs), the negative effects on bone 
regeneration are clear. However, leukotriene antagonists, which are currently FDA-
approved to treat chronic airway inflammation, have shown immense potential as agents 
to stimulate bone healing. The role of corticosteroids in this field remains unclear. In 
vivo, they have been shown to have a wide range of effects depending on factors 
including the method and temporal pattern of administration. This is a particularly 
important lesson for the development of future tissue engineering strategies, as the 
composition of the implanted material can profoundly affect the immune, and therefore 
inflammatory, response. 
Another very important lesson is the need for clinically realistic in vitro models of 
bone regeneration. Historically, bone tissue engineers have commonly used 
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dexamethasone, an anti-inflammatory corticosteroid, to stimulate in vitro osteogenic 
differentiation of MSCs and thus generate models of bone healing. However, comparison 
of in vitro results with the available in vivo studies of cytokine delivery has indicated this 
osteogenic supplement cannot be used when studying cytokine delivery. Concurrent 
delivery of corticosteroids and cytokines such as TNF -a to MSC cultures has resulted in 
findings that are completely opposite to those seen in vivo. Pre-treatment of MSCs with 
corticosteroids to stimulate in vitro osteogenic differentiation, followed by cytokine 
delivery alone, has yielded more realistic results. Important future directions for in vitro 
studies in this field include studies to elucidate the mechanisms underlying inflammatory 
signaling, additional optimization of cell culture models, as well as studies of the 
interplay between various cytokines and growth factors found at the fracture site. 
Learning to rationally control inflammation will provide a wealth of new directions in the 
development of bone tissue engineering strategies, and will ultimately improve the 
quality and specificity of therapies available to stimulate bone regeneration in patients 
with impaired healing or severe bone injuries. 
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Chapter 4 
Dose Effect of Tumor Necrosis Factor-a on In 
Vitro Osteogenic Differentiation of Mesenchymal 
Stem Cells on Biodegradable Polymeric 
Microfiber Scaffolds5 
Abstract: This study presents a first step in the development of a bone tissue engineering 
strategy to trigger enhanced osteogenesis by modulating inflammation. This work 
focused on characterizing the effects of the concentration of a pro-inflammatory cytokine, 
tumor necrosis factor alpha (TNF-a), on osteogenic differentiation of mesenchymal stem 
cells (MSCs) grown in a 3D culture system. MSC osteogenic differentiation is typically 
achieved in vitro through a combination of osteogenic supplements that include the anti-
5 This chapter was published as: Mountziaris PM, Tzouanas SN, Mikos AG. Dose Effect of Tumor 
Necrosis Factor-<alpha> on In Vitro Osteogenic Differentiation of Mesenchymal Stem Cells on 
Biodegradable Polymeric Micro fiber Scaffolds. Biomaterials 20 I 0; 31: 1666-1675. 
49 
inflammatory corticosteroid dexamethasone. Although simple, the use of dexamethasone 
is not clinically realistic, and also hampers in vitro studies of the role of inflammatory 
mediators in wound healing. In this study, MSCs were pre-treated with dexamethasone to 
induce osteogenic differentiation, and then cultured in biodegradable electrospun poly(e-
caprolactone) (PCL) scaffolds, which supported continued MSC osteogenic 
differentiation in the absence of dexamethasone. Continuous delivery of 0.1 ng/mL of 
recombinant rat TNF-a suppressed osteogenic differentiation of rat MSCs over 16 days, 
which was likely the result of residual dexamethasone antagonizing TNF -a signaling. 
Continuous delivery of a higher dose, 5 ng/mL TNF -a, stimulated osteogenic 
differentiation for a few days, and 50 ng/mL TNF -a resulted in significant mineralized 
matrix deposition over the course of the study. These findings suggest that the pro-
inflammatory cytokine TNF -a stimulates osteogenic differentiation of MSCs, an effect 
that can be blocked by the presence of anti-inflammatory agents like dexamethasone, 
with significant implications on the interplay between inflammation and tissue 
regeneration. 
4.1. Introduction 
The limitations of autologous bone grafting and other available surgical 
reconstructive techniques have led to increased interest in bone tissue engineering, an 
interdisciplinary strategy to promote healing of large bone defects using bioactive 
implantable materials. Cells and bioactive factors are incorporated into these scaffolds to 
provide temporal and spatial cues guiding bone regeneration (176). However, 
osteogenesis involves complex molecular signaling and induces significant changes in the 
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expression of several thousand genes (8, 30, 31). To develop an effective tissue 
engineering strategy for bone regeneration, the key regulators of this process must be 
identified and incorporated. Informed by cell biology research, efforts to date have 
focused on inducing bone regeneration via delivery of various bioactive molecules and 
osteoprogenitor cells. However, recent insight into the critical role of pro-inflammatory 
cytokines, including tumor nec;.osis factor alpha (1NF-a), in bone healing has heralded a 
new direction in the rational design ofbone tissue engineering constructs (104, 163). 
Although the impact of unregulated 1NF -a signaling on mature bone m 
osteoporosis, rheumatoid arthritis, and other pathologies has been studied, the role of 
1NF-a signaling during bone healing is not well understood (104, 120, 159, 160, 162). 
Recent studies suggest 1NF -a plays an important role in priming bone renewal. 
Expression of 1NF-a rises immediately following bone injury, and is elevated again in 
later stages of bone regeneration (38, 59, 104). Absence of this 1NF-a signaling impairs 
in vivo bone fracture healing in a mouse model, delaying endochondral ossification, but it 
has no effect on skeletal development, suggesting that 1NF -a plays a unique role in post-
natal osteogenesis (1, 2). We selected 1NF-a as a model inflammatory signal for our 
studies based on its significant impact on in vivo bone regeneration. 
Our ultimate goal is to develop a novel bone tissue engineering strategy that 
harnesses inflammation to trigger osteogenesis in large bone defects. However, due to the 
many gaps in our knowledge regarding the mechanism by which inflammatory signals 
trigger regeneration, we are first focusing on developing a 3D in vitro strategy to better 
characterize the role of 1NF -a on mesenchymal stem cells (MSCs) undergoing 
osteogenic differentiation. Here we present the results of a study that aimed to establish 
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the effect of 1NF -a concentration on osteogenic differentiation of MSCs cultured in vitro 
on biodegradable microfiber scaffolds. 
MSCs are a component of the bone marrow stroma, and have the capability to 
differentiate into various connective tissues, including bone (3). In vitro osteogenic 
differentiation of MSCs typically requires the addition of dexamethasone (3, 5, 9), an 
anti-inflammatory corticosteroid that is not found in the in vivo fracture healing 
microenvironment and that suppresses in vivo bone regeneration (1 04, 177). Further, 
dexamethasone is known to antagonize the in vitro effects of 1NF-a on osteoblasts (62). 
Recent efforts have resulted in 3D materials that support in vitro differentiation of MSCs 
without the need for dexamethasone, for instance, by means of a microfiber mesh 
scaffold coated with pre-generated bone-like extracellular matrix (6, 8, 9). 
In this study we used polymer electrospinning to generate porous mesh scaffolds 
made of poly(e-caprolactone) (PCL), a biocompatible and biodegradable polymer (178, 
179). By modulating key processing variables, including the PCL concentration, flow 
rate, collector distance, and applied voltage, PCL microfiber scaffolds with a specific 
pore size, porosity, and fiber diameter can be reproducibly generated (179). Scaffold pore 
size and porosity are key determinants of cell attachment and migration, and also of 
nutrient transport, all of which affect cell function, proliferation, and differentiation ( 180-
182). Electrospun PCL fibers with sub-micron diameters have been shown to enhance 
MSC adhesion and spreading (179). MSCs were pre-cultured to induce osteogenic 
differentiation, and then cultured on electrospun PCL microfiber meshes, which we 
assumed would continue to support MSC osteogenic differentiation even in the absence 
of dexamethasone. 
52 
This study addresses the following questions: (i) What is the impact of continuous 
TNF-a delivery for 4, 8, and 16 days, and (ii) what is the impact ofTNF-a concentration, 
on osteogenic differentiation of MSCs cultured in vitro in 3D biodegradable PCL 
microfiber scaffolds? MSC-seeded scaffolds were exposed to varying concentrations of 
TNF -a, which we hypothesized would enhance osteogenic differentiation in a dose-
dependent manner. Our ultimate goal was to determine the impact of TNF -a 
concentration on in vitro 3D osteogenic differentiation of MSCs. 
4.2. Materials and Methods 
4.2.1. Experimental Design 
A design with 6 groups and 3 time points was used to evaluate the impact of TNF-
a dose on rat MSC osteogenic differentiation on electrospun poly(s-caprolactone) (PCL) 
scaffolds. Low (0.1 ng/mL), medium (5 ng/mL), and high (50 ng/mL) rat TNF-a 
concentrations were continuously delivered over a 4, 8, or 16-day culture period. Three 
control groups were included: cell/scaffold constructs cultured without added TNF -a or 
dexamethasone; a positive control where constructs received dexamethasone (i.e., 
complete osteogenic media), but did not receive TNF-a; and an acellular control, where 
cell-free PCL scaffolds were cultured in the absence of both TNF-a and dexamethasone, 
in order to account for any non-cell-specific scaffold calcium accumulation. 
4.2.2. Electrospun Scaffold Generation 
The PCL (inherent viscosity = 1.22 dL/g; Lactel, Pelham, AL) had a number-
average molecular weight (Mn) = 72,100 ± 1400 Da, weight-average molecular weight 
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(Mw) = 115,000 ± 2200 Da, and polydispersity index (Mw!Mn) of 1.60 ± 0.02, determined 
via gel permeation chromatography (Phenogel Linear Column with 5 J..Lm particles, 
Phenomenex, Torrance, CA; Differential Refractometer 410, Waters, Milford, MA) using 
a calibration curve created from polystyrene standards (Fluka, Switzerland). The PCL 
was dissolved at 18 w/w% in 5: 1 (by vol) chloroform:methanol. This solution was used 
to generate electrospun meshes of PCL microfibers using a previously described 
apparatus consisting of a syringe pump (Cole Parmer, Vernon Hills, IL), power supply 
(Gamma High Voltage Research, Osmond Beach, FL), 19 em diameter copper wire (18 
gauge) ring, and a square grounded copper plate ( 11 x 11 x0.3 em) (179). Briefly, 9 mL of 
PCL solution were loaded into a 10 mL syringe to which a 16 gauge blunt-tip needle 
(Brico Medical Supplies, Inc., Metuchen, NJ) was attached. The syringe was positioned 
in the electrospinning apparatus such that the needle tip was 33 em from a glass 
collecting plate, placed immediately in front of the grounded copper plate, and 4 em from 
the copper ring used to direct the spinning fibers onto the plate. The positive lead from 
the power supply was split and connected to both the needle tip and the copper ring. A 
voltage difference of 33 kV was applied and the PCL solution was pumped out of the 
needle tip at 40 mL/h using the syringe pump. Disks with a diameter of 8 mm were cut 
from each resulting PCL microfiber mesh using an arch punch (C.S. Osborne & Co., 
Harrison, NJ). Those disks with thickness 0.90-1.10 mm, as measured using digital 
micro-calipers (Mitutoyo, Aurora, IL ), were used as scaffolds for the study. Two 
electrospun PCL meshes were required to generate a sufficient number of scaffolds for 
this study. The meshes were prepared on consecutive days from the same lot ofPCL, and 
using the same electrospinning parameters. 
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4.2.3. Scaffold Morphology 
For scanning electron microscopy (SEM), samples were mounted onto aluminum 
stubs and sputter-coated with 30 nm of gold. Fiber diameters at the top (n = 45 fibers) 
and bottom (n = 45 fibers) of each mesh were measured via SEM (FEI Quanta 400 
Environmental, Hillsboro, OR) at a 7.31 kV accelerating voltage and 3.0 spot size. The 
bottom of each mesh was defined as the side adjacent to the glass collecting plate, i.e., the 
first layer of electrospun PCL microfibers to be deposited. The top of the mesh (the side 
seeded with MSCs) was thus the final layer of microfibers to be deposited. Several 
methods were used to minimize bias in the fiber diameter measurements. Scaffolds for 
SEM imaging (n = 3) were blindly punched from widely separated regions of each PCL 
mesh. The coordinates of the areas to be imaged on each scaffold ( n = 3 on the top, n = 3 
on the bottom) were established prior to SEM, as was the (previously described) 
procedure for selecting and measuring fibers (n = 5 per field of view) (179). 
4.2.4. Scaffold Porosity 
The porosity of n = 50 scaffolds from each mesh was determined v1a an 
established gravimetric analysis protocol (179). Briefly, the porosity, e, was calculated 
based on the apparent density of the scaffold, Pscaffold, and the density of PCL, PPcL, 
according to the equation: e = 1 - PscaffolctiPPcL· To determine Pscaffold for each scaffold, 
mass and volume were measured. To calculate volume, each scaffold was approximated 
as a cylinder with 8 mm diameter and with height equivalent to the scaffold thickness 
measured with digital micro-calipers. 
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4.2.5. Mesenchymal Stem Cell Isolation 
Rat MSCs were isolated from the pooled femoral and tibial bone marrow of 8 
male syngeneic Fischer 344 rats weighing 150-175 g, according to established methods 
(8, 9). Bone marrow suspensions were cultured for 7 days in 75 cm2 flasks using 
complete osteogenic media, which consists of a-MEM containing 10% v/v fetal bovine 
serum (Gemini Bio-Products, West Sacramento, CA), 50 mg/L gentamicin, 1.25 J.tg/mL 
amphotericin-B (Sigma, St. Louis, MO), as well as 3 osteogenic supplements: 10-8 M 
dexamethasone, 0.01 mM ~-glycerophosphate, and 50 J.tg/mL ascorbic acid (all from 
Sigma), to induce osteogenic differentiation (5, 8). Culture media was changed on days 1, 
3, and 5 to remove non-adherent cells. In this study, the adherent cells are designated as 
"mesenchymal stem cells," based on the established osteogenic potential of this cell 
population under appropriate in vitro conditions (3, 183). 
4.2.6. TNF -a Reconstitution and Dilution 
56 
Rat TNF -a was used for this study to better model the in vivo biology of the rat 
MSCs, since combining TNF-a from one species (e.g., human TNF-a) with MSCs from 
another species (e.g., murine MSCs) has been reported to result in TNF-a receptor 
binding selectivity not seen with native TNF-a (184). Lyophilized recombinant rat TNF-a 
(R&D Systems, Minneapolis, MN) was reconstituted on the day of scaffold seeding using 
sterile phosphate-buffered saline (PBS) containing 0.1 w/w% bovine serum albumin 
(Sigma), according to the manufacturer's instructions. Aliquots were taken from this 100 
ng/J.tL stock TNF-a solution and further diluted to concentrations of0.1, 5, and 50 ng/J.tL. 
All reconstituted TNF-a solutions were split into aliquots, to minimize the number of 
freeze/thaw cycles, and stored at -20°C in a manual defrost freezer, according to the 
manufacturer's instructions. For experiments, 4 J.!L of diluted solution were added to 4 
mL of media used for construct culture, resulting in the desired experimental group 
concentrations of0.1, 5, and 50 ng/mL TNF-a. 
4.2. 7. Scaffold Preparation 
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Electrospun PCL scaffolds were prepared for MSC seeding according to 
established protocols (179). The scaffolds were sterilized via exposure to ethylene oxide 
gas for 14h, and then passed through a decreasing ethanol gradient (from 100% to 70%) 
to expel air from the scaffold pores. Centrifugation was used to ensure complete 
prewetting. The ethanol was exchanged with sterile milliQ water, and the scaffolds were 
then immersed in dexamethasone-free osteogenic media and left in an incubator 
overnight. Prior to MSC seeding, the scaffolds were press-fit into seeding cassettes and 
placed into 6-well plates (1 cassette/well). Ultra-low attachment 6-well plates (Coming 
Incorporated Life Sciences, Lowell, MA), consisting of a neutral, hydrophilic hydrogel 
covalently bound to a polystyrene well-plate, were used based on the results of a pilot 
study indicating increased retention of MSCs on electrospun PCL scaffolds (i.e., reduced 
adhesion of MSCs to the bottom of the well) without any impact on MSC osteogenic 
differentiation. 
4.2.8. Scaffold Seeding and Culture 
Nearly confluent MSCs were detached from the cell culture flasks with 0.25% 
trypsin!EDTA (Sigma, St. Louis, MO), counted with a hemocytometer, centrifuged, and 
resuspended at 1.25 million cells/mL in dexamethasone-free osteogenic media, which is 
identical in composition to complete osteogenic media, except that it lacks 
dexamethasone. Although dexamethasone is typically used as an osteogenic supplement 
in vitro (5, 9), it was not included in the media used for MSC/scaffold culture because 
this portion of the study involved TNF-a. supplementation, and dexamethasone has been 
shown to antagonize the in vitro effects of TNF-a. on osteoblasts (62). For seeding, 200 
J.LL of the resuspended MSCs were added drop-wise to each scaffold, which had already 
been press-fit into a seeding cassette and placed in a 6-well plate (Corning), as detailed 
above. MSCs were allowed to attach to the scaffolds for 4h, and then each well was filled 
with dexamethasone-free media as well as supplemental TNF-a. or dexamethasone, as 
appropriate. After 24h, cell/scaffold constructs (n = 15 per group) were transferred to new 
ultra-low attachment 6-well plates (1 construct/well). 4 mL of dexamethasone-free media 
were added to each well, and relevant groups also received supplemental TNF-a. (0.1, 5, 
or 50 ng/mL per well) or dexamethasone (10-8 M/well). Thereafter, media and 
supplements were changed every two days for a total of 4, 8, or 16 days of culture. 
4.2.9. Cellularity Measurement 
Construct cellularity was quantified according to an established protocol (9). At 
each timepoint, n = 4 constructs from each group were rinsed twice with PBS and placed 
in 1 mL of sterile milliQ water. The cells were lysed and cell contents were extracted 
with 3 freeze/thaw/sonication cycles (10 min at -so·c, 10 min at 3TC, 10 min 
sonication). The dsDNA content of each resulting solution was quantified using the 
fluorometric PicoGreen assay (Molecular Probes, Eugene, OR) with an excitation 
wavelength of 490 nm and an emission wavelength of 520 nm, as detailed elsewhere (9). 
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Samples and dsDNA standards were run in triplicate. The results were converted to cells 
per construct using the previously established DNA content of rat MSCs (9). 
4.2.10. Alkaline Phosphatase Activity Assay 
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Alkaline phosphatase (ALP) activity of MSC-seeded scaffolds was used as an 
early marker of osteogenic differentiation (9). An established colorimetric assay was used 
to quantify ALP activity based on the rate of conversion of a colorless substrate, p-
nitrophenyl phosphate disodium salt hexahydrate (Sigma), to a yellow product, p-
nitrophenol (9). The assay was prepared in a 96-well plate using aliquots of the same cell 
lysate used to measure cellularity, according to an established protocol (9). Samples were 
run in triplicate, and diluted to fall within the range of the p-nitrophenol standards. After 
1h incubation at 37°C, the reaction was stopped with 0.3 M NaOH and the absorbance at 
405 nm was measured with a plate reader. ALP activity was normalized to construct 
cellularity (9). 
4.2.11. Calcium Content Assay 
The acid-soluble calcium content of MSC-seeded scaffolds was used to quantify 
mineralized matrix deposition, which is a late-stage marker of osteogenic differentiation 
(9). An established colorimetric assay was used to quantify calcium content based on the 
color change that occurs when a calcium chelating agent (Arsenazo III, Diagnostic 
Chemicals, Oxford, CT) binds to free calcium in an acid solution. Prior to the assay, each 
construct was removed from the aqueous cell lysate, immersed in 1 mL 1 N acetic acid, 
and left on a shaker table at 200 rpm overnight to dissolve matrix-bound calcium. The 
assay was prepared in a 96-well plate as previously described, and absorbance at 650 nm 
was read after a 10 min incubation (9). Samples were run in triplicate and diluted to fall 
within the range of the CaCb standards. 
4.2.12. Histological Sample Preparation 
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At each timepoint, n = 1 construct from each group was rinsed twice with PBS 
and fixed overnight in 5 mL of 10% buffered formalin phosphate. Constructs were then 
passed through an ascending (70% to 100%) ethanol gradient and stored in 100% ethanol 
at 4 °C. Prior to sectioning, each construct was cut in half using a razor blade, so that 
cross-sectional images could be obtained. Half was returned to storage in 100% ethanol 
and the other half was embedded in HistoPrep frozen tissue embedding media (Fisher 
Scientific, Pittsburgh, P A). Frozen 5 J.Uil thick sections were cut using a cryotome 
(CM1850, Leica Microsystems, Bannockburn, IL) and mounted on Superfrost Plus glass 
slides (Fisher Scientific). The slides were incubated at 45°C on a slide warmer for 4-5 
days for optimal section adhesion. 
4.2.13. Histological Staining and Imaging 
To visualize the distribution of mineralized matrix and cells within each construct, 
sections were rehydrated with water for 1 min and then immersed in von Kossa stain (5% 
w/w silver nitrate in milliQ water) under UV for 30 min. Residual stain was removed by 
gentle drop-wise rinsing with water followed by 95% ethanol. Sections were then 
counter-stained with alcoholic eosin Y (Sigma) for 3 min. Residual eosin was removed 
by gentle drop-wise rinsing with 95% ethanol. Once dry, stained slides were imaged with 
a light microscope (Eclipse E600, Nikon, Melville, NY) using an attached video camera 
(3CCD Color Video Camera DXC-950P, Sony, Park Ridge, NJ) and computer. Light 
microscope images were calibrated using the standard two-image method to correct for 
differences in background lighting and in dark-current effects in the detector (185). 
4.2.14. Statistical Analysis 
Fiber diameters and porosities are reported as mean ± standard deviation for n = 
45 fibers and n = 50 scaffolds, respectively. The average fiber diameter of the top and 
bottom of each PCL microfiber mesh, along with the average porosity, were compared 
using a Student's t-test for two independent samples with equal variance (a= 0.05) after 
performing an F-test to validate the assumption of equal variance at 95% confidence. 
Cellularity, ALP activity, and calcium assay results are reported as mean ± standard 
deviation for n = 4 constructs. Statistical differences in cellularity, ALP activity, and 
calcium content amongst groups at each time point, and also within each group over time, 
were analyzed at 95% confidence using one-way analysis of variance. Multiple pair-wise 
comparisons were made using the Bonferroni post-hoc analysis method at 95% 
confidence. 
4.3. Results 
The two electrospun PCL microfiber meshes fabricated for this study had 
statistically equivalent mean fiber diameters (p > 0.05), as shown in Table 4.1. Although 
the average porosities of the two meshes were statistically different (p < 0.05), the 
magnitude of the difference was quite small (77.8 ± 2.8% vs. 79.5 ± 3.1 %), and so the 
two meshes were used to generate the PCL scaffolds for this study. Equal numbers of 
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scaffolds were randomly selected from each mesh. Figure 4.1 shows representative 
scaffold morphology obtained via SEM at varying magnifications. 
Table 4.1 Comparison of fiber diameters and porosites for the two electrospun 
meshes used for this study. 
Parameter for Comparison Value for Mesh 1 Value for Mesh 2 
Fiber Diametet, Top (ttm) 9.50 ± 1.57 9.37 ± 2.04 
Fiber Diameter, Bottom (pm) 11.58 ± 2.23 11.76± 1.79 
Porosity (%) 77.8 ± 2.8* 79.5 ± 3.1 * 
Values are presented as mean ± standard deviatiOn. The sample stze was n = 45 for fiber 
diameters from the top and bottom of each mesh, and n = 50 scaffolds for PCL mesh 
porosity. Pairs of values were compared and statistically significant differences (p < 0.05) 
are indicated with a "*." 
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Figure 4.1: Electrospun scaffold morphology. 
Electrospun microfibers generated for this study, imaged via SEM at varying 
magnifications, (a) 200 x, (b) 600x, and (c) 2000 x. A cross-section through the entire 
thickness of a representative scaffold is shown in (d), at 120x magnification. Scale bars 
shown for (a) and (b) represent 100 J.tm, 20 J.tm for (c), and 200 J.tm for (d). 
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Figure 4.2 depicts the number of cells in the constructs after 4, 8, and 16 days of 
culture. Most groups had similar cellularity at each timepoint, with a few exceptions. The 
acellular control ("Acellular") had nearly zero cells/scaffold at all timepoints, as 
expected. The cellularity of the positive control group ("0 ng/mL TNF +dex") peaked at 
the earliest timepoint (day 4), at a value significantly higher than the number of cells on 
the experimental constructs (p < 0.05). The number of cells on the positive control 
constructs subsequently declined (values at all three timepoints differ, p < 0.05), such that 
this group had significantly fewer cells than the other groups at day 16 (p < 0.05). The 
negative control group ("0 ng/mL TNF") followed a similar trend, although no statistical 
differences were detected between timepoints (p > 0.05). In contrast, the lowest dose of 
TNF-a ("0.1 ng/mL TNF") induced proliferation resulting in a monotonic increase in 
cellularity (values at all three timepoints differ, p < 0.05), with cell numbers for this 
group exceeding those of all others on days 8 and 16 (p < 0.05). The highest dose of 
TNF-a ("50 ng/mL TNF") also induced proliferation, but cellularity peaked at day 8 and 
then declined (day 4 and day 16 values both differ from day 8, p < 0.05). The middle 
dose of TNF -a ("5 ng/mL TNF") followed a similar trend, with an apparent peak at day 8 
and subsequent plateau, but no statistical differences were detected between timepoints (p 
> 0.05). 
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Figure 4.2: Scaffold cellularity over time. 
Cellularity of MSC-seeded electrospun PCL scaffolds after 4, 8, and 16 days of culture. 
Three freeze/thaw/sonication cycles were used to extract dsDNA, which was then 
quantified with a fluorometric kit and translated to cells/scaffold. Experimental groups 
were cultured in dexamethasone-free osteogenic media supplemented with 0.1 , 5, or 50 
ng/mL TNF-a (abbreviated "TNF" in the figure). Three control groups were included: a 
positive control supplemented with dexamethasone, but no TNF -a ("0 ng/mL TNF 
+dex"); a negative control cultured without any added dexamethasone ("0 ng/mL TNF"); 
and an acellular control, where cell-free PCL scaffolds were cultured in dexamethasone-
free media ("Acellular"). Each bar represents the mean ± standard deviation for n = 4 
constructs. Error bars are included for all groups, though they are too small to resolve for 
"Acellular." Statistical differences (p < 0.05) among groups at a single timepoint are 
indicated by"*" for a group that differs from all other groups, and"**" for a group that 
differs from only some groups. Changes over time are indicated by "#," meaning that 
values for that group at each timepoint are significantly different (p < 0.05). 
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Figure 4.3 shows the ALP activity of the constructs on a per cell basis. 
Dexamethasone induced ALP activity, such that the 0 ng/mL TNF +dex positive control 
had significantly higher values than all other groups at each timepoint (p < 0.05), and 
showed an increasing trend throughout the study (all timepoints different, p < 0.05). 
Unlike the positive control, the ALP activity of the 0 ng/mL TNF negative control did not 
change throughout the study (all timepoints similar, p > 0.05), although it did appear to 
be declining by day 16. In contrast, supplementation with TNF -a greatly reduced ALP 
activity on a per cell basis. The experimental groups had significantly lower ALP activity 
than both of the MSC-seeded control groups at all timepoints (p < 0.05). This suppression 
appeared dose-dependent on day 4 since 0.1 ng/mL TNF had higher ALP activity than 50 
ng/mL TNF (p < 0.05), and the value for 5 ng/mL TNF fell between these two. Although 
the ALP activity of 0.1 ng/mL TNF remained higher than that of the other two 
experimental groups at all timepoints (p < 0.05), these groups showed divergent trends 
over time. The ALP activity of 0.1 ng/mL TNF peaked at day 8 (all timepoints differ, p < 
0.05), while 5 ng/mL TNF and 50 ng/mL TNF had monotonically decreasing ALP 
activity (in each group, all timepoints differ, p < 0.05), that was indistinguishable from 
the acellular group by day 16 (p > 0.05). As expected, the acellular control had nearly 
zero ALP activity at all timepoints. 
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Figure 4.3: Scaffold alkaline phosphatase activity over time. 
Alkaline phosphatase (ALP) activity of MSC-seeded electrospun PCL scaffolds after 4, 
8, and 16 days of culture. Experimental groups were cultured in dexamethasone-free 
osteogenic media supplemented with 0.1, 5, or 50 ng/mL TNF-a (abbreviated "TNF" in 
the figure). Three control groups were included: a positive control supplemented with 
dexamethasone, but no TNF-a ("0 ng/mL TNF +dex"); a negative control cultured 
without any added dexamethasone ("0 ng/mL TNF"); and an acellular control, where 
cell-free PCL scaffolds were cultured in dexamethasone-free media ("Acellular"). Each 
bar represents the mean± standard deviation for n = 4 constructs. Error bars are included 
for all groups, though they are too small to resolve in some cases. Statistical differences 
(p < 0.05) among groups at a single timepoint are indicated by"*" for a group that differs 
from all other groups, and"**" for a group that differs from only some groups. Changes 
over time are indicated by"#," meaning that values for that group at each timepoint are 
significantly different (p < 0.05). 
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Figure 4.4 illustrates the acid-soluble calcium content of the constructs after 4, 8, 
and 16 days of culture. The calcium content of all groups, with the exception of the 
acellular control, monotonically increased over time. Dexamethasone induced the 
greatest amount of overall calcium deposition, such that the 0 ng/mL TNF +dex positive 
control had significantly higher values than all other groups on days 8 and 16 (p < 0.05), 
and showed an increasing trend throughout the study (all timepoints different, p < 0.05). 
TNF-a triggered early mineralized matrix deposition in a dose-dependent manner, such 
that 5 ng/mL TNF had significantly more calcium on day 4 than the control groups and 
0.1 ng/mL TNF (p < 0.05), and 50 ng/mL TNF had even more calcium (p < 0.05). After 
day 4, the rate at which calcium was deposited in these constructs declined, while the 
calcium deposition rate of the controls increased. By day 8, the negative control (0 ng/mL 
TNF) and 50 ng/mL TNF constructs had similar calcium content (p > 0.05), and 
continued to deposit similar amounts of calcium through day 16 (p > 0.05). On both days 
8 and 16, the calcium content of 0 ng/mL TNF and 50 ng/mL TNF significantly exceeded 
that of the other two experimental groups (p < 0.05). In fact, the lower doses of TNF-a 
almost completely suppressed calcium deposition. The mineralized matrix deposition rate 
of the 5 ng/mL TNF constructs fell to zero after day 4, so that essentially no further 
calcium was deposited over the course of the study. The calcium content of the 0.1 
ng/mL TNF constructs also plateaued; it increased (p < 0.05) from a near-zero level on 
day 4 to a level equivalent to the 5 ng/mL TNF constructs on day 8. Neither group 
showed any further calcium deposition on day 16 (p > 0.05). 
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Figure 4.4: Scaffold mineralization over time. 
Calcium content of MSC-seeded electrospun PCL scaffolds after 4, 8, and 16 days of 
culture. Experimental groups were cultured in dexamethasone-free osteogenic media 
supplemented with 0.1, 5, or 50 ng/mL TNF-a (abbreviated "TNF" in the figure). Three 
control groups were included: a positive control supplemented with dexamethasone, but 
no TNF-a ("0 ng/mL TNF +dex"); a negative control cultured without any added 
dexamethasone ("0 ng/mL TNF"); and an acellular control, where cell-free PCL 
scaffolds were cultured in dexamethasone-free media ("Acellular"). Each bar represents 
the mean ± standard deviation for n = 4 constructs. Error bars are included for all groups, 
though they are too small to resolve in some cases. Statistical differences (p < 0.05) 
among groups at a single timepoint are indicated by"*" for a group that differs from all 
other groups, and"**" for groups that do not differ from each other, but differ from all 
other groups. Changes over time are indicated by"#," meaning that values for that group 
at each timepoint are significantly different (p < 0.05). 
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The results of the cellularity and calcium content assays were confirmed 
qualitatively through histological analysis, shown in Figure 4.5. Sections were stained 
with von Kossa, which stains mineralized extracellular matrix black, and counter-stained 
with eosin, which dyes cytoplasmic material and organic matrix components (e.g., 
collagen) reddish-pink. The highest density of mineralized matrix was observed at the top 
of the scaffolds, visible as black deposits of varying widths and ---40 J.tm thickness (blue 
arrows in Figure 4.5). Consistent with the calcium assay data (Figure 4.4), 50 ng/mL 1NF 
sections stained the darkest with von Kossa on day 4, while 0 ng/mL 1NF +dex was the 
darkest-staining group on days 8 and 16 (Figure 4.5). The presence of the black-stained 
mineralized matrix made it difficult to discern the cells in sections with high calcium 
because the matrix was co-localized with cells. 
In general, the highest density of cells was observed at the top of the scaffolds. At 
the earliest timepoint, when the calcium content of all groups was at its lowest, a 5-10 J.lffi 
thick pink-stained layer of cells and non-mineralized matrix was visible at the top of each 
section (indicated by yellow arrows), except for the acellular construct (Figure 4.5). 
Consistent with cellularity (Figure 4.2) and calcium measurements (Figure 4.4), a very 
thick (~30 J.tm) reddish-pink layer of cells and (mostly non-mineralized) matrix was 
observed on the top surface of the 0.1 ng/mL 1NF sections on days 8 and 16 (see 
representative images in Figure 4.5). Cells infiltrated 200-500 J.tm into each microfiber 
scaffold; these lower-density collections of cells gave the upper ~200 J.tm of the section a 
grayish tint (e.g., day 8 image of 0 ng/mL 1NF in Figure 4.5), and/or appeared as grayish 
threads and speckles amidst the PCL fibers (e.g., yellow arrows in lower half of day 16 
image ofO ng/mL 1NF in Figure 4.5). The grayish color ofthese features is an artifact of 
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the low magnification (lOx) used to capture the images in Figure 4.5. At higher 
magnification (not shown), these structures were tinted pink, as expected for eosin-
stained cells. Mineralized matrix was also deposited on PCL fibers 200-500 J.lm below 
the surface, consistent with the depth of cell infiltration. This was particularly evident 
when comparing the lower portions of the stained sections (e.g., day 16 images of 0 
ng/mL TNF +dex, 0 ng/mL TNF, and Acellular in Figure 4.5). 
CD 
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Figure 4.5 - part 1 (continued on next page) 
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Figure 4.5: Representative histological images from each timepoint. 
Representative cross-sectional images (5 J.!m thick) of stained MSC-seeded electrospun 
PCL scaffolds after 4, 8, and 16 days of culture. Sections were stained with von Kossa 
and eosin. Each image shows only the top half of each cross-section, which is where cells 
(representative examples indicated by yellow arrows) and mineral deposits 
(representative examples marked with blue arrows) were located. Experimental groups 
were cultured in dexamethasone-free osteogenic media supplemented with 0.1 , 5, or 50 
ng/mL TNF-a (abbreviated "TNF" in the figure). Three control groups were included: a 
positive control supplemented with dexamethasone, but no TNF -a ("0 ng/mL TNF 
+dex"); a negative control cultured without any added dexamethasone ("0 ng/mL TNF"); 
and an acellular control, where cell-free PCL scaffolds were cultured in dexamethasone-
free media ("Acellular"). Images were captured at 1 Ox original magnification. Scale bar 
in lower right comer represents 200 J.!m and applies to all images. 
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4.4. Discussion 
The goal of this study was to determine the effect of TNF -a dose on MSC 
osteogenic differentiation in a 3D biodegradable microfiber mesh scaffold. The lowest 
TNF-a concentration (0.1 ng/mL) for this study was selected because it approximates the 
physiologic level of TNF -a measured in wound fluid from patients with severe bone 
injuries (67). The medium (5 ng/mL) and high TNF-a concentrations (50 ng/mL) were 
selected based on previous studies demonstrating differential effects on the 2D 
osteogenic differentiation ofMSCs (158, 160, 162). We found that continuous delivery of 
a low dose (0 .1 ng/mL) of recombinant rat TNF -a suppressed osteogenic differentiation 
of rat MSCs over 16 days. In contrast, continuous delivery of a higher dose, 5 ng/mL 
TNF -a, stimulated osteogenic differentiation for a few days, and 50 ng/mL TNF -a 
resulted in significant mineralized matrix deposition over the course of the study. Our 
findings suggest that TNF -a stimulates osteogenic differentiation of MSCs, and that this 
effect can be antagonized by signaling resulting from pre-culture with the anti-
inflammatory agent dexamethasone. 
An important feature of this study is the use of TNF -a and MSCs from the same 
species. Recombinant rat TNF-a was used to better model the in vivo biology, since the 
MSCs were from a rat source. Rats were selected in anticipation of future in vivo 
implantation studies to evaluate bone regeneration using an established rat critical size 
cranial defect model (186). To our knowledge, no other studies have reported on the ALP 
activity and mineralized matrix deposition of rat MSCs treated with rat TNF -a in vitro 
either in 2D or 3D culture. Several previous studies with rat osteoprogenitors have inter-
mingled species; for instance, fetal rat calvarial osteoblasts were treated with recombinant 
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human TNF -a, resulting in decreased calcium deposition when TNF -a was given during 
the first two weeks of culture, and no effect if TNF -a administration began thereafter 
(187, 188). However, inter-species variability in TNF-a is significant, as shown 
rigorously for humans and mice. Human TNF -a selectively binds to the type 1 TNF 
receptor on murine MSCs, while murine TNF -a has equal affinity for both type 1 and 2 
TNF-a receptors (184). Thus, it is difficult to use the results of these studies to better 
understand the in vivo impact of TNF-a. Additionally, studies using MSCs and TNF-a 
from the same species have shown divergent effects. Human MSCs treated in vitro with 
htiman TNF-a for 14-21d showed increased ALP activity and calcium deposition (159, 
160), while recombinant murine TNF-a (also delivered for 14-21d) suppressed ALP 
activity and mineralized matrix deposition of murine MSCs (162, 189). This suggests that 
species physiology affected our osteogenic marker results. 
Our results indicate that unmodified electrospun PCL microfiber meshes support 
3D osteogenic differentiation of MSCs. This was not seen in similar in vitro studies with 
titanium microfiber meshes, where scaffolds required a pregenerated bone-like 
mineralized matrix coating in order to support in vitro rat MSC osteogenic differentiation 
under static conditions, particularly in the absence of dexamethasone (9). In this study, 
the calcium per construct achieved in the 0 ng/mL TNF +dex positive control constructs 
after 16 days (Figure 4.4) far exceeds the values reported for MSC-seeded titanium 
microfiber meshes under similar in vitro conditions (644.5 ± 14.9 f.,lg vs. 10-20 f..lg), and is 
similar to the net calcium deposition achieved when the titanium microfibers were coated 
with pregenerated bone-like matrix (9). Similarly, the 407.6 ± 14.1 f..lg of calcium 
deposited after 16 days in the absence of dexamethasone (0 ng/mL TNF values in Figure 
----------- ~------
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4.4) exceeds that for both unmodified (~0 J..tg) and bone-like matrix coated (213.2 ± 13.6 
J..tg) titanium microfiber constructs (9). Several potential explanations for these findings 
exist. The batch of MSCs used for this study may have had inherently higher capacity for 
mineralized matrix deposition. This is a less likely explanation, however, since the MSCs 
from 5 or more rats were pooled to reduce such variability. Additionally, similar high 
calcium values have been achieved in pilot studies using MSC-seeded PCL scaffolds 
(results not shown). The hydrophobicity of the PCL microfibers may have played a role 
by promoting protein adsorption and subsequent cell adhesion, which may have enhanced 
osteogenic differentiation. PCL was selected for the generation of electrospun microfiber 
scaffolds because of its biocompatibility and very slow degradation rate, such that 
scaffolds implanted in vivo as a component of a future bone tissue engineering strategy 
would promote tissue ingrowth and provide structural support within a bone defect, and 
then later degrade to allow for remodeling of the regenerated bone (179, 182). The 
variation in fiber size inherent to the generation of electrospun PCL meshes may have 
been beneficial, compared to the relatively uniform prefabricated titanium meshes. SEM 
indicated that although largely comprised of ~ 10 J..lm diameter fibers, the PCL meshes 
also contained some smaller fibers (Figure 4.1 a,b ). Electro spun PCL fibers with sub-
micron diameters have been shown to enhance rat MSC adhesion and spreading (179). 
The results of this study indicate that electrospun PCL microfiber meshes are promising 
candidates as components of 3D in vitro culture systems to better understand the role of 
inflammatory mediators in MSC osteogenic differentiation. 
We capitalized on this finding to culture MSCs in the absence of dexamethasone, 
which was particularly important as this anti-inflammatory corticosteroid blocks the in 
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vitro effects of TNF-a on osteoblasts (62). Corticosteroids, including dexamethasone, 
interfere with intracellular TNF -a signaling mainly by binding to and inactivating nuclear 
factor-KB (NF-KB), a transcription factor (177). TNF-a binding to cell-surface receptors 
activates NF-KB, which travels from the cell cytoplasm to the nucleus, binds to DNA, and 
activates specific genes. Antagonizing NF-KB blocks many effects of TNF-a on cells 
(177). Unlike TNF-a, corticosteroids are not found in the in vivo fracture healing 
microenvironment and have been shown to suppress in vivo bone regeneration (104, 177). 
Thus, the exclusion of dexamethasone from the culture media of all but the positive 
control group had the benefit of making the 3D culture system described herein a better 
approximation of in vivo bone biology. 
However, dexamethasone is commonly used for in vitro MSC culture, in 
combination with ascorbic acid and p-glycerophosphate, due to the resulting significant 
stimulation of osteogenic markers like ALP activity and mineralized matrix deposition (3, 
5, 9). In this study, all three of these supplements were provided to the rat MSCs during 
the 2D pre-culture expansion period based on previous reports that dexamethasone is 
necessary to initiate in vitro osteogenic differentiation of rat MSCs (3, 9). 
Dexamethasone supplementation was discontinued once the MSCs were seeded onto the 
biodegradable PCL microfiber scaffolds, i.e., during the portion of the study involving 
TNF-a supplementation. The only exception was the 0 ng/mL TNF +dex positive control 
group, which received continuous dexamethasone supplementation and as a result 
showed elevated markers of osteogenic differentiation, with the highest level of ALP 
activity throughout the study (p < 0.05; Figure 4.3) and the highest level of calcium 
deposition on days 8 and 16 (p < 0.05; Figure 4.4). 
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The decrease in cellularity over time observed in the 0 ng/mL TNF +dex positive 
control (Figure 4.2; values at all three timepoints differ, p < 0.05) is consistent with our 
previous experience with rat MSC osteogenic differentiation on titanium meshes (20 J.llll 
fiber diameter) (9) and starch-PCL blend (180 J.lm fiber diameter) scaffolds (182). Two 
possible explanations for this decline in measured cellularity over time have been 
reported. One possibility is that it is an artifact of late-stage osteogenic differentiation of 
MSCs, which results in increased deposition of mineralized matrix that traps DNA and 
prevents its detection (9). The 0 ng/mL TNF +dex constructs exhibited high levels of 
calcium deposition on days 8 and 16 (Figure 4.4), a trend confirmed by von Kossa 
staining (Figure 4.5). Histology also indicated that calcified matrix co-localized with cells 
and the (eosin-stained) cell content of the 0 ng/mL +dex constructs appeared to increase 
over time, particularly from days 4 to 8 (Figure 4.5), suggesting that complete DNA 
detection may have been impaired by the high mineralized matrix content of these 
constructs. This mechanism could also be applied to the subtly declining cell counts seen 
in the dexamethasone-free negative control (Figure 4.2; non-significant decreasing trend 
for 0 ng/mL TNF constructs, p > 0.05), and also to the 50 ng/mL TNF group, where 
measured cellularity declined significantly from day 8 to day 16 (Figure 4.2; p < 0.05); 
this finding was not seen with the other two doses of TNF -a. At the same time, calcium 
content of the 0 ng/mL TNF and 50 ng/mL TNF constructs increased significantly 
(Figure 4.4; all three timepoints differ within each group, p < 0.05) and greatly exceeded 
that for the other two TNF-a doses on days 8 and 16 (Figure 4.4;p < 0.05). 
Another possible explanation for the decrease in cellularity over time observed in 
the 0 ng/mL TNF +dex positive control (Figure 4.2; values at all three timepoints differ, p 
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< 0.05) is a direct effect of dexamethasone, which is known to support MSC proliferation 
in some cases and inhibit it in others. Factors influencing this effect include 
dexamethasone dose and duration, as well as MSC species and stage of osteogenic 
differentiation (3). Under this theory, the subtle decline in cellularity seen for the 0 
ng/mL TNF (Figure 4.2; non-significant decreasing trend, p > 0.05) and 50 ng/mL groups 
(Figure 4.2; significant decline from days 8-16, p < 0.05) would be attributable to end-
stage osteogenic differentiation of the MSCs, associated with cessation of cell 
proliferation, decreased early-stage markers (in this study, ALP activity shown in Figure 
4.3; non-significant decreasing trend for 0 ng/mL TNF, p > 0.05, and significant 
decreasing trend for 50 ng/mL TNF, p < 0.05), and elevated late-stage markers (here, 
mineralized matrix deposition in Figure 4.4; significant increasing trends for 0 ng/mL 
TNF and 50 ng/mL TNF, p < 0.05). In contrast, the substantial decrease in cell content of 
the 0 ng/mL TNF +dex constructs (Figure 4.2; cellularity lower than all other groups 
except acellular on day 16, p < 0.05) would be the combined result of terminal MSC 
differentiation into osteoblasts and a direct effect of dexamethasone on cellularity. 
Further studies are required to distinguish between these two possibilities. 
Overall, no adverse effect of 0.1 - 50 ng/mL TNF-a on cell viability was seen 
over the course of 16 days, consistent with recent reports for 2D in vitro MSC cultures in 
dexamethasone-free osteogenic media (159, 160). Although cell counts in the 
experimental constructs were lower than in the controls on day 4 (p < 0.05), this 
difference was no longer present by day 8 (Figure 4.2). The monotonic increase in 
cellularity over time for 0.1 ng/mL TNF constructs (Figure 4.2; values at all three 
timepoints differ, p < 0.05) is consistent with proliferation recently reported for human 
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MSCs encapsulated in 3D poly( ethylene glycol)-based hydro gels and exposed to 
recombinant human TNF -a for 14 days in the presence of dexamethasone (163 ). This 
increase in proliferation was suggested to indicate that TNF -a inhibits osteogenic 
differentiation of human MSCs, particularly when combined with data indicating that 
TNF-a suppressed ALP activity of human MSCs in the hydrogels (163). However, it is 
likely that these published results reflect the combined, opposing effects of TNF -a and 
dexamethasone delivery. 
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In this study, the divergent effects of low and high doses of TNF -a on markers of 
MSC osteogenic differentiation likely arose from the relative balance between 
dexamethasone- and TNF-a-related signaling early in 3D culture. Our results for the 0.1 
ng/mL TNF constructs suggest that TNF-a inhibited osteogenic differentiation, but the 
data for the 50 ng/mL TNF group suggest the opposite. Previous studies have reported 
one result or the other, but never a combination of the two findings as in our case. The 
most likely explanation is a residual effect of the dexamethasone that was used as a 
supplement during the MSC in vitro pre-culture period. Corticosteroids, including 
dexamethasone, are internalized by cells and bind to an intracellular receptor, so the in 
vitro effects of dexamethasone can persist for up to 2 weeks after its removal from the 
environment (3 , 177). Thus, despite the separation in the delivery of dexamethasone and 
TNF -a during MSC culture, our results suggest that intracellular signals arising from the 
two agents interacted and impacted MSC osteogenic differentiation. 
The 7-day pre-culture period used for the rat MSCs in this study typically results 
in committed osteoprogenitor cells that are not yet mature osteoblasts (132). By day 4 of 
our study, TNF-a had reduced ALP activity (Figure 4.3; p < 0.05) and increased 
mineralized matrix deposition (Figure 4.4; p < 0.05) in a dose dependent manner. 
However, this effect was not maintained over the course of 16 days for lower doses of 
TNF-a. The ALP and calcium data for the 0.1 ng/mL TNF group indicate suppressed 
osteogenic differentiation over the course of 16 days. Both osteogenic markers were 
significantly lower than the values for positive and negative control groups throughout 
the study (ALP activity suppressed, p < 0.05 in Figure 4.3; calcium content reduced, p < 
0.05 in Figure 4.4). When considered together with the cellularity data, where the 0.1 
ng/mL constructs showed a monotonic increase in cell content (Figure 4.2; all three 
timepoints differ, p < 0.05), these data are consistent with previous reports of 
simultaneous delivery of dexamethasone and TNF -a, which stimulated an immature, 
proliferative phenotype in human MSCs (163). In contrast, the highest dose ofTNF-a had 
the opposite effect on MSCs; cell content remained fairly constant throughout the study 
(Figure 4.2), while mineralized matrix content increased monotonically (Figure 4.4; all 
three timepoints differ, p < 0.05), consistent with progression towards terminal 
osteogenic differentiation and with previous reports of human MSCs treated with human 
TNF-a in the absence of dexamethasone (159, 160). The 5 ng/mL TNF constructs 
showed a similar pattern, with constant cellularity (Figure 4.2), declining ALP activity 
(Figure 4.3; all three timepoints differ, p < 0.05), and significantly elevated mineralized 
matrix content on day 4 (Figure 4.4; exceeds all groups except 50 ng/mL TNF, p < 0.05). 
However, mineralized matrix deposition appeared to halt after day 4 for this group, so 
that the values on days 8 and 16 were equivalent to those of the 0.1 ng/mL TNF 
constructs (Figure 4.4; p > 0.05). Thus, the lowest dose of TNF-a may have only been 
sufficient to cancel out the effects of dexamethasone, halting MSC osteogenic 
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differentiation, while the higher doses were able to also exert a TNF -a-related effect on 
the MSCs, resulting in increased calcium deposition. 
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Our findings of increased mineralized matrix deposition triggered by TNF -a 
delivery in the absence of dexamethasone are supported by several studies in a variety of 
cell types. TNF-a delivered for 28d in the absence of dexamethasone promoted 
odontoblastic differentiation and increased mineralized matrix deposition of dental pulp 
cells (161). Increased calcium deposition in vitro has also been reported for vascular-
derived cells treated with TNF -a in the absence of dexamethasone (190). In addition, 
human MSCs treated in vitro with human TNF-a for 14-21d showed increased calcium 
deposition in the absence of dexamethasone (159, 160). However, a similar study in 
murine MSCs indicated that recombinant murine TNF -a suppressed ALP activity and 
mineralized matrix deposition regardless of the presence of dexamethasone (162, 189), 
which serves as a reminder that species physiology also impacted our results. Overall, our 
results suggest that the pro-inflammatory cytokine TNF-a stimulates in vitro mineralized 
matrix deposition by MSCs, a late-stage marker of osteogenic differentiation, and that 
this effect is likely antagonized by the anti-inflammatory agent dexamethasone. Future 
studies will expand on this exciting finding to establish the optimal time period for 
delivery and, ultimately, whether TNF-a can be used as a more physiologically realistic 
replacement to the traditional osteogenic supplement dexamethasone. 
4.5. Conclusions 
This study demonstrated that the pro-inflammatory cytokine TNF-a stimulates 
mineralized matrix deposition, a late stage marker of osteogenic differentiation, when 
delivered continuously to MSCs cultured in 3D electrospun PCL microfiber meshes. By 
day 4 of our study, TNF -a had reduced ALP activity, an early marker of osteogenic 
differentiation, and increased mineralized matrix deposition in a dose dependent manner. 
However, this effect was not maintained over the course of 16 days for lower doses of 
TNF -a. Continuous delivery of 0.1 ng/mL of TNF -a induced proliferation and suppressed 
osteogenic markers in MSCs over 16 days, an effect that likely arose from the 
antagonism of TNF-a by anti-inflammatory signaling induced by the corticosteroid 
dexamethasone, which was used as an osteogenic supplement during in vitro MSC pre-
culture. In contrast, continuous delivery of a higher dose, 5 ng/mL TNF -a, stimulated 
osteogenic differentiation for a few days, and 50 ng/mL TNF -a resulted in significant 
mineralized matrix deposition over the course of the study. This suggests that the lowest 
dose of TNF -a was only sufficient to cancel out the effects of dexamethasone, halting 
MSC osteogenic differentiation, while the higher doses were able to also exert a TNF -a-
related effect on the MSCs, resulting in increased calcium deposition. Based on these 
results we conclude that TNF -a stimulates osteogenic differentiation, and that its effects 
on MSCs can be blocked by the presence of anti-inflammatory agents like 
dexamethasone. 
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Chapter 5 
Effect of Temporally Patterned TNF- a Delivery 
on In Vitro Osteogenic Differentiation of 
Mesenchymal Stem Cells 
5.1. Introduction 
Craniofacial bone is a dynamic tissue that is constantly resorbed and renewed, and 
has the remarkable capacity to regenerate. However, this regenerative process, which is 
dependent on adequate temporal and spatial distribution of molecular and cellular signals, 
fails in bone defects above a critical size, resulting in impaired or completely absent 
osseous union ( 41 ). The limitations of current surgical reconstruction techniques have 
stimulated interest in tissue engineering. Informed by cell biology research, efforts to date 
have focused on inducing bone regeneration via delivery of various bioactive molecules, 
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particularly osteogenic factors. However, recent insight into the critical role of pro-
inflammatory cytokines, particularly tumor necrosis factor-a (TNF -a), in bone healing 
has heralded a new direction in the rational design of bone tissue engineering constructs 
(191). 
TNF -a is best known for its key roles in regulating acute inflammation, systemic 
immune responses, and osteoclast-mediated bone resorption. However, recent studies 
have unveiled another important role in priming bone renewal. Expression of TNF -a rises 
immediately following bone injury, and is elevated again in later stages of bone 
remodeling (38, 59, 104). Absence of this TNF-a signaling impairs in vivo bone fracture 
healing in a mouse model, delaying endochondral ossification, but it has no effect on 
skeletal development, suggesting that TNF -a plays a unique role in post-natal 
osteogenesis (1, 2). Motivated by this significant impact on in vivo bone regeneration, we 
previously examined the effect of varying TNF -a doses on in vitro osteogenic 
differentiation of mesenchymal stem cells (MSCs). We demonstrated that continuous 
delivery of 50 ng/ml TNF-a to mesenchymal stem cells (MSCs) stimulates mineralized 
matrix deposition, a marker of osteogenic differentiation (14). 
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This work built upon this previous finding and explored the effects of temporal 
variations in TNF -a delivery on MSC osteogenic differentiation. MSCs were cultured in 
3D biodegradable electro spun poly( epsilon-caprolactone) (PCL) scaffolds for 4-16 days 
and exposed to continuous, early, intermediate, or late TNF-a delivery. The early and late 
patterns mimicked the biphasic pattern of TNF-a signaling observed in vivo after bone 
fracture (see Figure 2.1) (1 04). The goal of this study was to investigate the effects of 
early, intermediate, late, and continuous temporal patterns of TNF-a delivery on MSC 
osteogenic differentiation. 
5.2. Methods and Materials 
5.2.1. Experimental Design 
This study had a three-factor design with 2 pre culture conditions ("+dex" vs. "-
dex"), 4 TNF-a delivery periods ("Continuous," "Early," "Intermediate," and "Later"), 
and 3 time points, as depicted in Figure 5 .1. All experimental groups received the same 
concentration (50 ng/ml) of TNF-a during the various delivery periods. Negative control 
groups consisted of MSCs (either +dex or -dex precultured) on PCL scaffolds cultured in 
-dex media without TNF -a. The positive control consisted of +dex precultured MSCs that 
continued to receive +dex media following seeding onto PCL scaffolds. Due to the large 
number of groups in this study, the design was repeated twice; the MSCs for each trial 
were obtained from independent isolations, and (n = 4) scaffolds per group per timepoint 
were included in each trial. 
5.2.2. Electrospun Scaffold Generation 
Electrospun PCL meshes were prepared according to an established protocol (14). 
The PCL (Lactel, Pelham, AL) had a number-average molecular weight (Mn) of 72,1 00 ± 
1400 Da and polydispersity index (Mw!Mn) of 1.60 ± 0.02, determined via gel permeation 
chromatography (Phenogel Linear Column with 5 J..Lm particles, Phenomenex, Torrance, 
CA; Differential Refractometer 41 0, Waters, Milford, MA) using a calibration curve 
generated with polystyrene standards (Fluka, Switzerland). An 18 w/w% solution of PCL 
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in 5:1 (by vol) chloroform: methanol was loaded into a 10 ml syringe and positioned in a 
previously described electrospinning apparatus (14, 179). A 16 gauge blunt-tip needle 
(Brico Medical Supplies, Inc. , Metuchen, NJ) was attached to the syringe such that the 
needle tip was 33 em from a glass collecting plate placed in front of the system's 
grounded copper plate. A voltage difference of 33 kV was applied to the needle tip and 
the PCL solution was pumped out of the needle tip at 40 mllh using a syringe pump. 
Preculture 
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Figure 5.1: Schematic of TNF -a temporal variation study. 
OM = Osteogenic Media (a-MEM, 10% v/v fetal bovine serum, 50 J..Lg gentamicin/ml, 
1.25 J..Lg amphotericin-B/ml, 10 mM ~-glycerophosphate, 50 J..Lg/ml ascorbic acid) either 
with or without 1o-8 M dexamethasone ("+dex" vs. "-dex"). 
Scaffolds with 8 mm diameter were cut from the resulting electrospun PCL 
meshes using an arch punch (C.S. Osborne & Co. , Harrison, NJ). The thickness of each 
scaffold was measured using digital micro-calipers (Mitutoyo, Aurora, IL) and, for 
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consistency with previous work (14), scaffolds with thickness 0.90-1.10 mm were used 
for the study. For each MSC isolation, (n = 2-3) electrospun PCL meshes were required 
to obtain a sufficient number of scaffolds for the study. Each batch of meshes was 
prepared on the same day using the same lot of PCL and the same electrospinning 
parameters. Scaffolds were stored under an inert nitrogen atmosphere at -20°C in a non-
defrosting freezer to prevent degradation prior to use. 
5.2.3. Scaffold Characterization 
For each electrospun mesh, (n = 3) scaffolds were mounted onto aluminum stubs, 
sputter-coated with 30 nm of gold, and imaged using scanning electron microscopy 
(SEM) (FEI Quanta 400 Environmental, Hillsboro, OR) at a 7.31 kV accelerating voltage 
and 3.0 spot size. Predefined coordinates on each scaffold were imaged and the diameters 
of (n = 45 fibers) from the top and (n = 45 fibers) from the bottom of each mesh were 
measured using an established protocol (14, 179). The porosity of n =50 scaffolds from 
each mesh was determined via an established gravimetric analysis protocol (14, 179) 
(detailed in Methods of previous chapter). 
5.2.4. Mesenchymal Stem Cell Isolation 
All MSC isolations were approved by the Rice University Institutional Animal 
Care and Use Committee and adhered to the National Institutes of Health guidelines. For 
each of the two independent trials described in the Experimental Design, MSCs were 
isolated from the pooled femoral and tibial bone marrow of 8 male syngeneic Fischer 344 
rats weighing 150-175 g, according to established methods (8, 9). Bone marrow 
suspensions from each rat were split into two portions and were cultured in either +dex or 
-dex media for 7 days. Both types of media consisted of a-MEM (Sigma, St. Louis, MO) 
with 10% v/v fetal bovine serum (Gemini Bio-Products, West Sacramento, CA), 50 
~g/ml gentamicin, 1.25 ~J.g/ml amphotericin-B, 10 mM ~-glycerophosphate, and 50 !J.g/ml 
ascorbic acid (all from Sigma). The +dex media also contained 10-8 M dexamethasone 
(Sigma). Culture media was changed on days 1, 3, and 5 to remove non-adherent cells. 
As in previous studies, the adherent cells were designated as "mesenchymal stem cells," 
based on the established osteogenic potential of this cell population under appropriate in 
vitro conditions (3, 14, 183). 
Although the fetal bovine serum used in this study was from the same 
manufacturer (Gemini) as that used in the previous study (previous chapter; (14)), it was 
derived from a different serum lot and was found to affect MSC differentiation as well as 
response to TNF -a. Thus, the previous TNF -a dosage study (14) was repeated with the 
new serum to establish a baseline for comparison of the results of the temporal patterning 
study. MSCs for this TNF-a dosage study were isolated from (n = 5) rats and all 
procedures were performed as previously described (14) (see Methods of previous 
chapter). 
5.2.5. TNF -a Reconstitution and Dilution 
Recombinant rat TNF -a (R&D Systems, Minneapolis, MN) was reconstituted at 
50 ng/~J-1 on the day of scaffold seeding using sterile phosphate-buffered saline (PBS) 
containing 0.1 w/w% bovine serum albumin (Sigma), according to the manufacturer's 
instructions. For experiments, 4 !J.l of TNF -a stock solution were added to 4 ml of media 
used for construct culture, resulting in the desired 50 ng/ml TNF -a. 
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5.2.6. Scaffold Seeding and Culture 
Prior to MSC seeding, the scaffolds were sterilized via exposure to ethylene oxide 
gas for 14h and prewet using a decreasing ethanol gradient (from 100% to 70%), 
according to established protocols (14, 179). The ethanol was exchanged with sterile 
milliQ water, and then with -dex media. The next day, the scaffolds were press-fit into 
seeding cassettes, placed into ultra-low attachment 6-well plates (1 cassette/well) 
(Coming Incorporated Life Sciences, Lowell, MA), and seeded with MSCs. 
89 
For seeding, nearly confluent MSCs were lifted from the cell culture flasks with 
0.25% trypsin/EDTA (Gibco, Carlsbad, CA), counted with a hemocytometer, 
centrifuged, and resuspended at 1.25 million cells/ml in -dex osteogenic media. 0.2 ml of 
the resuspended MSCs were added drop-wise to each scaffold, which had already been 
press-fit into a seeding cassette. 
After waiting 4h to allow for MSC attachment to the scaffolds, each well was 
filled with 8 ml of -dex media and the relevant groups were supplemented with either 1 o-8 
M dexamethasone or 50 ng/ml TNF-a (according to the design shown in Figure 5.1 ). 
After 24h, the constructs were removed from the seeding cassettes and transferred to new 
ultra-low attachment 6-well plates for the duration of the study. The wells were filled 
with 4 ml of -dex media, supplemented with dexamethasone or TNF -a as appropriate, 
and media were changed every two days thereafter. 
5.2.7. Cellularity, Alkaline Phosphatase Activity, and Calcium Content Assays 
For each of the two independent trials of the TNF -a temporal study, on days 4, 8, 
and 16, (n = 4) scaffolds from each group were removed, rinsed twice with 4 ml of PBS, 
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and flash-frozen in 1 ml of sterile milliQ water using liquid nitrogen. The cells were lysed 
using three consecutive freeze/thaw/sonication cycles (1 0 min at -80°C, 10 min at 37°C, 
10 min sonication). The double-stranded DNA content of each resulting cell lysate 
solution was quantified using the fluorometric PicoGreen assay (Molecular Probes, 
Eugene, OR) and then converted to the number of cells per construct (9, 14). The alkaline 
phosphatase (ALP) activity of the cell lysates was quantified using an established 
colorimeteric assay based on the rate of conversion of the colorless substrate p-
nitrophenyl phosphate disodium salt hexahydrate (Sigma), to a yellow product, p-
nitrophenol (9, 14). Next, each construct was removed from the aqueous cell lysate, 
immersed in 1 ml 1 N acetic acid, and left on a shaker table at 200 rpm overnight to 
dissolve matrix-bound calcium. Calcium content was quantified using an established 
colorimetric assay that is based on a calcium chelating agent (Arsenazo III; Genzyme 
Diagnostics PEl, Charlottetown, Prince Edward Island, Canada) that changes color upon 
binding to free calcium in an acid solution. Samples and standards were run in triplicate 
for all assays. Samples were diluted as necessary to fall within the range of the standards 
for each assay. A detailed experimental procedure for each of these biochemical assays is 
provided in the previous chapter and has also been published (9, 14). 
5.2.8. Histological Sample Preparation and Analysis 
At the final timepoint, n = 1 construct from each of the three control groups and 
from the two "continuous" TNF -a groups was rinsed twice with PBS and fixed overnight 
in 5 ml of 10% buffered formalin phosphate. Constructs were then passed through an 
ascending (70% to 100%) ethanol gradient and stored in 100% ethanol at 4 °C. Prior to 
sectioning, each construct was cut in half (so that cross-sectional images could be 
obtained) and embedded in HistoPrep (Fisher Scientific, Pittsburgh, PA). Frozen 5 J..tm 
thick sections (CM1850 cryotome, Leica Microsystems, Bannockburn, IL) were mounted 
on Superfrost Plus slides (Fisher Scientific) and incubated at 45°C on a slide warmer for 
4-5 days according to an established protocol for optimal section adhesion (14). 
Sections were rehydrated and then stained with von Kossa (5% w/w silver nitrate 
in milliQ water) under UV for 30 min. The slides were rinsed with water followed by 
95% ethanol and then alcoholic eosin Y (Sigma) was applied as a counter-stain for 3 min. 
Excess eosin was removed with 95% ethanol. The slides were allowed to air dry, and 
then imaged with a light microscope (Eclipse E600, Nikon, Melville, NY) equipped with 
a camera (3CCD Color Video Camera DXC-950P, Sony, Park Ridge, NJ) and attached to 
a computer. Light microscope images were calibrated using the standard two-image 
method to correct for differences in background lighting and in dark -current effects in the 
detector (185). 
5.2.9. Statistical Analysis 
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Fiber diameters and porosities are reported as mean ± standard deviation for n = 
45 fibers and n = 50 scaffolds, respectively. The average fiber diameter of the top and 
bottom of each PCL microfiber mesh, along with the average porosity, were compared at 
95% confidence using one-way analysis of variance. For the temporal variation study, the 
biochemical assay results are reported as mean ± standard deviation for n = 8 constructs 
(n = 4 constructs from each of two independent trials). The cellularity, ALP activity, and 
calcium content data from each of the two trials were combined and analyzed as a 
randomized complete block design at 95% confidence using two-way analysis of 
variance. Each trial was set as a block. Multiple pair-wise comparisons were made using 
the Bonferroni post-hoc analysis method at 95% confidence. For the TNF-a dosage 
study, the cellularity, ALP activity, and calcium content values represent the mean ± 
standard deviation for n = 4 constructs from each group at each timepoint. The data were 
compared using one-way analysis of variance with 95% confidence. 
5.3. Results and Discussion 
5.3.1. Scaffold Morphology 
The morphology of representative scaffolds from each study is shown in Figure 
5.2, imaged via SEM at varying magnifications. The average fiber diameter and porosity 
of each mesh used in this study is listed in Table 5.1. With the exception of the second 
repetition of the temporal TNF-a study ("Trial 2" in Table 5.1), the PCL microfiber 
meshes generally had statistically equivalent mean fiber diameters (p > 0.05), as shown in 
Table 5.1. For the second repetition of the temporal study, one mesh had a slightly higher 
than average fiber diameter ( ~ 11 ~m). Although nearly every mesh had a statistically 
unique porosity, the magnitude of the differences was quite small, with the values 
ranging from 78.8 ± 1.4% to 84.9 ± 0.9% across all meshes. 
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Figure 5.2: Morphology of representative scaffolds via SEM. 
Representative electrospun PCL meshes generated for this study, imaged via SEM at 
varying magnifications, (a,d,g) 300x, (b,e,f) 600x, and (c,f,i) 2000x. Scaffolds shown in 
the top (a-c) and middle ( d-f) rows are from the meshes used for the first and second 
repetitions of the temporal study, respectively. The bottom row (g-i) depicts scaffolds 
used for the TNF -a dosage study described in this chapter. Scale bars shown for ( c,f,i) are 
20 ~m. All other scale bars 1 00 J.!m. 
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Table 5.1 Comparison of fiber diameters and porosites of the electro spun meshes 
used for this study. 
Temporal Triall Trial2 Repeat of Dosage Study 
Parameter 
Mesh 1 2 3 4 5 Mesh 6 7 8 
Fiber 10.0 ± 9.6 ± 9.9± 11.1± 9.0 ± 8.9 ± 8.6 ± 8.3 ± Diameter, 1.0 1.5 1.5 1.1 * 1.3** 1.9** 1.9** 1.8** Top (pm) 
Fiber 
Diameter, 10.7 ± 10.0 ± 11.2 ± 15.9 ± 12.5 ± 11.0 ± 10.4 ± 12.0 ± 
Bottom 1.2 1.9 2.0 1.9* 1.4** 1.6 1.2 1.7** 
(pm) 
Porosity 80.1 ± 84.4 ± 83.9 ± 78.8 ± 81.7 ± 80.4 ± 83.3 ± 84.9± 
(Ofo) 1.6 1.0* 1.4* 1.4* 0.9* 2.6 1.0* 0.9* 
Values are presented as mean ± standard deviation. The sample size was n = 45 for fiber 
diameters from the top and bottom of each mesh, and n =50 scaffolds for porosity. For 
each parameter, * indicates values that significantly differ from all other values (p < 
0.05), while * * indicates groups of values that differ from all other values (p < 0.05), but 
not from each other. 
5.3.2. Construct cellularity 
Figure 5.3 depicts construct cellularity at each timepoint. The positive control 
group ( +dex preculture/+dex culture/0 ng/mL TNF), the +dex precultured negative 
control group (+dex/-dex/0 ng/mL TNF), and the +dex precultured continuous TNF-a 
group (+dex/-dex/50 ng/mL TNF for days 0-16) (Figure 5.3) in this study had analogous 
groups in the previous study (0 ng/mL TNF +dex, 0 ng/mL TNF, and 50 ng/mL TNF, 
respectively; Figure 4.2). For all three groups, the number of cells on the scaffolds at day 
4 in this study (Figure 5.3) was approximately half of the previous value (Figure 4.2). 
This difference can be attributed to the change in the batch of fetal bovine serum used as 
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a supplement in the culture medium, which in turn affected the attachment, proliferation, 
and/or survival of MSCs on the PCL scaffolds. 
The cellularity of the positive control group ( +dex/+dex/0 ng/mL TNF) followed 
a similar trend to that seen in the previous study (Figure 4.2), with a dramatic drop in cell 
number on day 16. This group had significantly fewer cells than any other group on day 
16 (p < 0.05)6. In contrast, the negative (+dex/-dex/0 ng/mL TNF) control group showed 
a peak in cellularity on day 8 (Figure 5.3) that was not observed in the previous study 
(Figure 4.2) . 
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MSCs precultured with osteogenic supplements ("preculture +dex") and dexamethasone-
naive MSCs ("preculture -dex") were seeded on PCL scaffolds and cultured for 16 days 
in dexamethasone-free media ("culture -dex"; the only exception is the positive control). 
Experimental groups were exposed to continuous (days 0-16), early (days 0-4 ), 
intermediate (days 4-8), or later (days 8-12) delivery of 50 ng/ml TNF-a. Each bar 
6 Note that an acellular control was not included in this study because no significant biochemical activity 
was seen for the acellular constructs in the previous study. 
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represents the average ± standard deviation of (n = 8) scaffolds per group at each 
timepoint. For each timepoint, letters (A-D) indicate statistically equivalent (p > 0.05) 
groups. Groups that are not marked with the same letter differ significantly (p < 0.05). 
Also, groups marked with* differ from all other groups at that timepoint (p < 0.05). For 
each group, # indicates that values at each timepoint for this group differ (p < 0.05), 
while+ indicates that the day 16 value differs from day 4 value (p < 0.05). 
The continuous TNF-a group (+dex/-dex/50 ng/mL TNF from days 0-16) showed 
a monotonic increase in cellularity over days 4-16, a trend not observed in the previous 
study (Figure 4.2), but observed for all groups receiving TNF-a in this study (Figure 5.3), 
as well as for the dexamethasone-naive negative control ( -dex/-dex/0 ng/mL TNF). 
Continuous delivery of TNF -a induced elevated cell numbers on day 16 compared to all 
other groups, although the difference was not statistically significant (p > 0.05). 
5.3.3. Construct ALP activity 
ALP activity was used as an early marker of osteogenic differentiation (Figure 
5.4). The positive control (+dex preculture/+dex culture/0 ng/mL TNF), negative (+dex/-
dex/0 ng/mL TNF) control, and +dex-precultured continuous TNF-a (+dex/-dex/50 
ng/mL TNF for days 0-16) groups had similar trends in ALP activity compared to those 
previously observed in the TNF-a dosage study (Figure 4.3). Specifically, the positive 
control group (+dex/+dex/0 ng/mL TNF) showed a monotonic increase in ALP activity, 
while the +dex precultured continuous TNF-a group (+dex/-dex/50 ng/mL TNF for days 
0-16) showed a monotonic decrease in ALP activity. The ALP activity of the +dex 
precultured negative control group (+dex/-dex/0 ng/mL TNF) remained fairly constant 
over time (Figure 5.4). Although the trends remained consistent, the change in serum 
batch caused the magnitude of the ALP activity to increase, which is evident in 
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comparing the y-axis of Figure 5.4 (maximum value: 50 pmol/hr/cell) to that of Figure 
4.3 (maximum value: ~ 7 pmol/hr/cell) . 
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Figure 5.4: ALP activity with various TNF -a temporal patterns 
MSCs precultured with osteogenic supplements ("preculture +dex") and dexamethasone-
naive MSCs ("preculture -dex") were seeded on PCL scaffolds and cultured for 16 days 
in dexamethasone-free media ("culture -dex"; the only exception is the positive control) . 
Experimental groups were exposed to continuous (days 0-16), early (days 0-4), 
intermediate (days 4-8), or later (days 8-12) delivery of 50 ng/ml TNF-a. Each bar 
represents the average ± standard deviation of (n = 8) scaffolds per group at each 
timepoint. For each timepoint, letters (A-J) indicate statistically equivalent (p > 0.05) 
groups. Groups that are not marked with the same letter differ significantly (p < 0.05). 
Also, groups marked with* differ from all other groups at that timepoint (p < 0.05). For 
each group, # indicates that values at each timepoint for this group differ (p < 0.05), 
while + indicates that the day 16 value differs from day 4 value (p < 0.05). 
TNF -a delivery suppressed ALP activity 1n both +dex precultured and 
dexamethasone-naive MSCs (Figure 5.4). However, this suppression of ALP activity by 
TNF -a was reversible; both the +dex and -dex precultured versions of the groups that 
received "early" (days 0-4) or "intermediate" (days 4-8) TNF -a had significantly higher 
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(p < 0.05) ALP activity on day 16 compared to day 8. Continuous delivery of 50 ng/ml 
TNF-a caused a monotonic decrease in ALP activity (values at all timepoints differ for 
+dex and -dex preculture groups, p < 0.05), which was in stark contrast to the monotonic 
increase seen in all three control groups (+dex/+dex, +dex/-dex, and -dex/-dex). 
Consistent with previous results (Figure 4.3), the day 16 ALP activity of the +dex/+dex 
control group greatly exceeded that of all other groups (p < 0.05), with the +dex 
precultured negative control group (+dex/-dex) having the second highest day 16 ALP 
activity (p < 0.05). 
5.3.4. Construct mineralization 
Mineralized matrix deposition, shown in Figure 5.5 , was used as a late marker of 
osteogenic differentiation. Since the study of TNF -a dose effects indicated that TNF -a 
supports continued osteogenic differentiation of MSCs in the absence of dexamethasone 
(Figure 4.4), this study included experimental and control groups with dexamethasone-
naive MSCs to determine whether TNF -a is sufficient to trigger osteogenic 
differentiation. However, mineralized matrix deposition was only observed in +dex-
precultured cells (+dex preculture differs from -dex preculture, p < 0.05) (Figure 5.5 ; 
note that the y-axis is plotted on a logarithmic scale), indicating that TNF -a is not 
sufficient to trigger MSC osteogenic differentiation. This finding is consistent with 
previous reports of the effects of TNF -a on undifferentiated human MSCs; TNF -a 
significantly affected the in vitro protein expression, proliferation, and migration of the 
cells, but did not induce any type of differentiation (111, 157). 
Consistent with previous results, both TNF -a and dexamethasone supported 
continued osteogenic differentiation and calcium deposition of +dex precultured MSCs. 
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As in previous studies (Figure 4.4; "0 ng/mL TNF +dex" group), the +dex/+dex positive 
control had the highest day 16 calcium content of any group (p < 0.05; Figure 5.5). 
Continuous delivery of TNF-a also significantly (p < 0.05) increased mineralized matrix 
deposition on days 8 and 16 compared to the negative control. TNF -a delivery during 
days 0-4 and 4-8 also resulted in a slight increase in day 16 calcium content (differ from 
all other groups but not each other, p < 0.05). Although the amount of TNF-a-induced 
calcium deposition on day 16 was an order of magnitude smaller in this study (+dex/-
dex/50 ng/mL TNF for days 0-16; Figure 5.5) than in the previous study (50 ng/mL TNF; 
Figure 4.4), it significantly exceeded the calcium content of the +dex precultured 
negative control (p <0.05). 
1000 
Preculture dex 
Culturedex 
CultureTNF 
(days) 
-
. 
*+ 
* ~r-I 
I I 
I 
+ + 
+ -
- -
+ 
** 
If + r..f I~r 
1 
- + -
- - -
-
0-16 0-16 
Day 4 
• Day 8 
• Day 16 
+ + 
** ** I..r r~- Jrf I..r~ I{ w 
I I I 
+ 
-
+ - + -
- - - - - -
0-4 0-4 4-8 4-8 8-12 8-12 
Figure 5.5: Construct mineralization with varying TNF -a temporal patterns 
MSCs precultured with osteogenic supplements ("preculture +dex") and dexamethasone-
naive MSCs ("preculture -dex") were seeded on PCL scaffolds and cultured for 16 days 
in dexamethasone-free media ("culture -dex"; the only exception is the positive control). 
Experimental groups were exposed to continuous (days 0-16), early (days 0-4), 
intermediate (days 4-8), or later (days 8-12) delivery of 50 ng/ml TNF-a. Each bar 
represents the average ± standard deviation of (n = 8) scaffolds per group at each 
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timepoint. Groups marked with* differ from all other groups at that timepoint (p < 0.05). 
For each group,+ indicates that the day 16 value differs from day 4 value (p < 0.05). 
5.3.5. Cell and mineral distribution by histology 
Cellularity and calcium content values were qualitatively confirmed v1a 
histological analysis of day 16 constructs using von Kossa, which stains mineralized 
matrix black, and eosin, which stains cells and non-mineralized matrix reddish-pink 
(Figure 5.6). Consistent with the calcium assay data (Figure 5.5), the +dex/+dex positive 
control group stained much darker and contained more calcium deposits (blue arrows) 
than any other group. 
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Figure 5.6: Scaffold cell and mineral distribution visualized via histology 
Representative cross-sections of MSC-seeded PCL scaffolds after 16 days of culture. 
MSCs were precultured in complete osteogenic media (+dex) or in dexamethasone-free 
media (-dex). The positive control (+dex/+dex) continued to receive dexamethasone after 
MSCs were seeded onto the scaffold. All other MSC/scaffold constructs were cultured in 
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dexamethasone-free media. Experimental groups shown were continuously supplemented 
with 50 ng/mL TNF-a (abbreviated "TNF" in the figure). 5 ).!m thick sections were 
stained with von Kossa, which stains mineralized matrix black (blue arrows), and eosin, 
which stains cells and non-mineralized matrix reddish-pink (yellow arrows). An image of 
an acellular scaffold is included for reference. Images were captured at 1 Ox original 
magnification. Scale bar in upper left corner represents 200 J.tm and applies to all images. 
The highest concentration of calcium deposits (blue arrows) and cells (yellow 
arrows) were observed in the top half of each construct (Figure 5.6). A 5-10 ).!m pink-
stained layer of cells and non-mineralized matrix was visible at the top of each section 
(indicated by yellow arrows), except for the acellular scaffold (Figure 5.6). In some areas, 
particularly in the +dex/+dex control, the pink color of the cells was obscured by the dark 
black color of the calcium deposits. As seen previously for similar electrospun PCL 
scaffolds cultured under static conditions ((14); Figure 4.5), cells infiltrated 200-500 ).!m 
into each microfiber scaffold (yellow arrows). 
5.3.6. Effect of new serum batch on response to varying TNF -a concentration 
Since the cellularity, ALP activity, and calcium content of three groups in this 
study that were also included in the previous study (previous chapter; (14)) differed in 
magnitude and also in trends over time, the TNF -a dosage study (14) was repeated with 
the new serum to establish a new baseline for comparison of the temporal results shown 
above. Figure 5.7 depicts the cellularity, ALP activity, and calcium content of MSC-
seeded scaffolds given varying TNF -a concentrations in media supplemented with the 
batch of serum used for the temporal results shown earlier in this chapter. 
101 
a 
6 
Acellular 
• 0 ng/mL TNF +dex + 
-5 0 ng/mL TNF **+ 
"0 
~ 0. 1 ng/mL TNF 
IV 5 ng/mL TNF (,) 
.!?4 
• 50 ng/mL TNF 
.!! 
'i (,) 
0 q3 
8 
~ 
~2 
IV 
~ 
~ 1 
0 
Day4 DayS Day 16 
b 
2.5 
, 2 
~ 
IV (,) 
..!? 
~ 1.5 
"6 
E 
~ 
> ~ 
0.. 
~ 
~ 0.5 
0 
Day4 DayS Day16 
Figure 5. 7: Construct cellularity, ALP activity, and calcium content with varying 
TNF -a concentrations in new serum. 
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Figure 5.7: Construct cellularity, ALP activity, and calcium content with varying 
TNF -a concentrations in new serum. 
The previously published study examining the effect of varying TNF -a dosage on MSC 
differentiation ( 14) was repeated using media supplemented with a different batch of fetal 
bovine serum. Cellularity over time is shown in (a). ALP activity on a per scaffold basis 
is shown in (b), while the same data on a per cell basis are shown in (c) with the 
exception of the acellular group. Calcium content is shown in (d). The insets in (b-d) 
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depict the full height of the bar for the day 16 positive control (0 ng/mL 1NF +dex). Bars 
re~re~ent ~verag~ ±standard deviation of (n = 4) scaffolds per group at each timepoint. 
Wtthin a tlmepomt, groups with* differ from all other groups (p < 0.05), while** differ 
from all other groups but not each other (p < 0.05). On day 16, +indicates that d4 and 
d16 values of that group differ (p < 0.05), while# indicates that values at all timepoints 
differ (p < 0.05). 
Figure 5.7a depicts construct cellularity at each timepoint. By comparing Figure 
5.7a to Figure 4.2, which shows the same groups cultured in the previous batch of fetal 
bovine serum, it is evident that the change in the batch of serum affected the attachment, 
proliferation, and/or survival of the MSCs on the PCL scaffolds. Since serum is derived 
from blood by removing the cellular components and clotting factors, its composition can 
vary greatly from batch to batch. Each batch of serum can differ in terms of the 
concentration of any number of substances, including antibodies, hormones, growth 
factors, and cytokines. For human MSCs, serum selection often involves an extensive 
screening process (3), but serum for MSCs from other species is not always subjected to 
such rigorous screening. These procedures may need to be revised as more complicated 
in vitro cell culture models are developed. 
Although the results in Figure 5.7a differ from those in Figure 4.2, they are 
consistent with the cellularity trends reported earlier in this chapter. Consistent with the 
results in Figure 5.3, the number of cells on the scaffolds at day 4 in the new serum batch 
(Figure 5.7a) was approximately half of the previous value (Figure 4.2). As in the 
previous 1NF-a dosage study, most of the groups had similar cell numbers at each 
timepoint. The acellular constructs ("Acellular") had nearly zero cells at all timepoints, as 
expected. The positive control ("0 ng/ml TNF +dex") group showed similar patterns in 
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both studies; the dramatic drop in cellularity at day 16 previously observed for this group 
in both Figure 4.2 and Figure 5.3 also occurred in this study. In contrast, the cellularity of 
the negative control group ("0 ng/mL TNF") showed a peak at day 8 that was not 
observed in the previous study (Figure 4.2), where this group had nearly constant cell 
numbers. However, this day 8 peak in cellularity was consistent with the trend observed 
for the analogous group in Figure 5.3 (+dex/-dex/0 ng/mL TNF). The significant 
monotonic increase in cellularity previously observed in the 0.1 ng/mL TNF group 
(Figure 4.2) was not seen in this study; instead, a dramatic increase in cellularity from 
day 8 to day 16 was observed in the 5 and 50 ng/mL TNF groups (Figure 5.7a). This 
increase is consistent with the change in cellularity of the +dex precultured continuous 
TNF-a group (+dex/-dex/50 ng/mL TNF for days 0-16) shown in Figure 5.3, confirming 
that this change in the response to TNF -a resulted from the change in serum. 
The ALP activity in response to varying TNF-a concentrations in the new batch 
of serum is shown in Figure 5.7b,c. Consistent with the findings earlier in this chapter 
(Figure 5.4), the change in the serum affected the magnitude of ALP activity, but the 
trends for the groups remained similar. For example, for the three groups with the highest 
ALP activity on days 8 and 16 (i.e., 0 ng/mL TNF +dex, 0 ng/mL, and 0.1 ng/mL TNF), 
the ALP activity was at least 2-fold higher on day 8 and 5- to 10-fold higher on day 16 
with the new serum batch (Figure 5.7c) compared to the previous serum (Figure 4.3). The 
ALP activity per cell (Figure 5.7c) was not calculated for the acellular constructs, as their 
near-zero cellularity would artificially raise the ALP activity values. Instead, the ALP 
activity per scaffold for the acellular constructs and for all other groups is depicted in 
Figure 5.7b. For the MSC-seeded constructs, the "per cell" and "per scaffold" ALP 
105 
activities followed similar trends since the cellularity of the constructs was fairly constant 
(Figure 5.7a). 
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As in the previous study (Figure 4.3) and in the results of the temporal study 
(Figure 5.4) earlier in this chapter, a dramatic increase in the ALP activity of the 0 ng/mL 
TNF +dex positive control was seen from days 8-16; this group again had a much higher 
(p < 0.05) ALP activity than all other groups on day 16 (see insets in parts b and c of 
Figure 5.7 for full size ofthis bar). Unlike the study with the previous serum batch, where 
the ALP activity of the 0 ng/mL TNF negative control did not change (Figure 4.3), there 
was a monotonic increase in ALP activity per cell in this study. The negative control had 
significantly higher ALP activity than all other groups on days 4 and 8 (p < 0.05), and the 
second-highest value on day 16 (p < 0.05). This trend is consistent with the ALP activity 
ofthe analogous group (+dex/-dex/0 ng/mL TNF) shown in Figure 5.4. 
For both batches of serum, TNF-a suppressed the ALP activity of the MSCs in a 
dose-dependent fashion. The 0.1 ng/mL TNF group had much higher ALP activity than 
the other two TNF-a groups at all timepoints (Figure 5.7b,c), with a monotonic increase 
in ALP activity over time that paralleled that of the negative control group. In contrast, 
the groups with higher TNF -a dose had monotonic decreases in ALP activity over time, a 
trend that was also observed in the previous studies (Figure 4.3 and Figure 5.4). 
The change in the batch of serum dramatically affected construct mineralization 
(Figure 5.7d). The new serum batch was selected based on its ability to induce 
comparable calcium deposition to the previous batch of serum when used as a component 
of +dex media for MSCs growing in a 2D layer. For both sera, the acellular control 
showed no mineralization over time and the positive control (0 ng/mL TNF +dex) had 
significantly higher (p < 0.05) calcium content than all other groups on day 16. However, 
a comparison ofthe +dex positive control in Figure 5.7d (maximum y-axis value of30 f..tg 
(inset: 300 f..tg)) and in Figure 4.4 (maximum y-axis value 700 f..tg) suggests that the new 
serum was not equivalent to the previous serum in terms of its impact on MSC osteogenic 
differentiation in 3D electrospun PCL scaffolds. 
The negative control group (0 ng/mL TNF; Figure 5.7) had significantly lower (p 
< 0.05) day 16 calcium content than the 5 and 50 ng/mL TNF groups, which is consistent 
with the findings for the analogous groups in the study described earlier in this chapter 
(+dex/-dex/0 ng/mL TNF and +dex/-dex/50 ng/mL TNF for days 0-16; Figure 5.5) but 
differs from the statistically equivalent mineralization reported in Figure 4.4. This low 
calcium content for the 0 ng/mL TNF negative control was repeatedly observed in studies 
in our laboratory, suggesting that the previous study (Figure 4.4) had a unique component 
that induced this effect. 
The new serum had several significant effects on TNF -a-induced construct 
mineralization. In the previous study (Figure 4.4), TNF-a triggered early dose-dependent 
mineralized matrix deposition by day 4. In this study (Figure 5.7d), although the day 4 
calcium content of all TNF -a groups was equivalent to that seen with dexamethasone, it 
was significantly higher than that of the negative control (p < 0.05). A somewhat similar 
trend was observed for the analogous groups in Figure 5.5, where the +dex precultured 
continuous TNF-a group (+dex/-dex/50 ng/mL TNF for days 0-16) had slightly higher 
calcium content than the +dex precultured negative control (+dex/-dex/0 ng/mL TNF), 
although in that case the trend was not significant (p > 0.05) and the positive control had 
significantly higher calcium content than all other groups (p < 0.05) (Figure 5.5). 
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By day 8 of the TNF-a dosage study shown in Figure 5.7d, the 0.1 ng/mL TNF 
group no longer exhibited elevated calcium content, but the 5 and 50 ng/mL TNF groups 
continued to have calcium values significantly higher than that of the negative control on 
both days 8 and 16 (p < 0.05). Previously (Figure 4.4), both the 0.1 ng/mL TNF and 5 
ng/mL TNF groups showed suppressed calcium deposition, which was assumed to reflect 
the antagonism between residual signaling from the dexamethasone used during MSC 
preculture (to induce osteogenic differentiation) and the TNF -a delivered during the 
study (14). However, this suppression was not seen with the current serum, suggesting 
that the prior suppression may have been attributable to a TNF -a antagonist (e.g., native 
corticosteroids or soluble TNF-a receptors) present in the serum used for that study. 
In summary, the results of this new baseline study indicated that TNF-a stimulates 
construct mineralization in a dose-dependent fashion. Although the new serum resulted in 
a variety of changes in the biochemical assay results, the 50 ng/mL TNF group once 
again had the highest mineralization of all the experimental groups and was thus the 
appropriate TNF-a concentration to use in the temporal variation study. 
To our knowledge, no other studies have examined the temporal effects ofTNF-a 
on MSC osteogenic differentiation. However, several studies have reported that TNF-a 
causes a dose-dependent increase in mineralized matrix deposition when delivered to 
osteoprogenitors in media lacking dexamethasone (14, 112, 159-161). While 
dexamethasone is commonly used in in vitro MSC cultures, it is not present in the in vivo 
bone fracture environment; in fact, delivery of corticosteroids impairs bone fracture 
healing (104). Thus, the results ofthis study are not only important for understanding the 
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role of TNF -a in bone regeneration, but are also a useful step toward the development of 
a more clinically realistic in vitro model of the fracture healing microenvironment. 
5.4. Conclusions 
This study demonstrated that continuous delivery of the pro-inflammatory 
cytokine TNF -a is the optimal temporal pattern to induce osteogenic differentiation of 
MSCs cultured in 3D electrospun PCL microfiber meshes. Continuous 16-day exposure 
to 50 ng/ml TNF-a was compared with early (days 0-4), intermediate (days 4-8), and 
later (days 8-12) delivery. Since TNF-a has been shown to support continued osteogenic 
differentiation of MSCs in the absence of dexamethasone, an anti-inflammatory agent 
that is commonly used to stimulate in vitro MSC osteogenic differentiation and is 
typically required for continued differentiation, this study included experimental and 
control groups with dexamethasone-na'ive MSCs to determine whether TNF -a is 
sufficient to trigger osteogenic differentiation. Mineralized matrix deposition was not 
observed in constructs with dexamethasone-na'ive MSCs, indicating that TNF -a does not 
induce osteogenic differentiation of MSCs, but instead stimulates and supports 
progression toward terminal differentiation. 
For MSCs precultured with osteogenic supplements, TNF-a suppressed ALP 
activity, an early marker of osteogenic differentiation, and stimulated mineralized matrix 
deposition, a late stage marker of MSC osteogenic differentiation. The results for the 
brief temporal delivery periods included in this study demonstrated that the TNF-a-
induced suppression of ALP activity is reversible once exposure to TNF -a ceases, and 
that TNF -a stimulates some mineralized matrix deposition when delivered at any time 
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during the first 8 days of MSC culture. After 16 days of culture, dexamethasone-
precultured MSCs that were continuously exposed to TNF -a had the second-highest 
amount of mineralized matrix deposition. The calcium content of these constructs was 
significantly greater than that of both negative controls and was exceeded only by the 
positive control group. 
By elucidating the impact of temporal variations in TNF-a delivery, as well as the 
interplay between TNF-a and the anti-inflammatory osteogenic supplement 
dexamethasone, our results greatly improve our understanding of the impact ofTNF-a on 
in vitro MSC osteogenic differentiation. These findings will facilitate the design of future 
in vitro and in vivo experiments to probe the interplay of TNF -a with other growth factors 
and cytokines typically present at the site of bone injury and regeneration, which will 
ultimately enable the design of new strategies to rationally control TNF -a signaling and 
stimulate bone regeneration. 
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Chapter 6 
The Interplay of Bone-Like Extracellular Matrix 
and TNF -a Signaling on In Vitro Osteogenic 
Differentiation of MSCs 
6.1. Introduction 
Inflammation is an immediate response to bone injury, and a growing body of 
evidence indicates that the signaling cascades initiated during the week-long acute 
inflammatory response play a critical role in priming bone regeneration (105, 108, 191). 
Bone fracture alters the expression of over 6000 genes, including genes encoding 
inflammatory cytokines as well as a variety of growth factors (30). Together with growth 
factors, fracture-induced inflammatory mediators promote regeneration, e.g., by 
promoting angiogenesis and guiding mesenchymal stem cell (MSC) differentiation (105, 
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108, 191). Several cytokines, including tumor necrosis factor alpha (TNF-a), interleukin-
6 (IL-6), and stromal cell-derived factor-1 (SDF-1), have been shown to directly 
modulate the migration ofMSCs in vivo (109-112). 
Further studies into the impact of TNF -a on MSC osteogenic differentiation have 
been motivated by the recognition of its important role during in vivo bone regeneration. 
TNF-a expression increases immediately after bone injury, returning to baseline after a 
few days, and is elevated again in later stages of bone remodeling (38, 59, 104). In an 
animal model lacking TNF-a, fracture healing was severely impaired and bone formation 
was delayed by several weeks (1, 2). In an in vivo fracture healing model, repeated local 
injections of TNF-a in the first few days after injury resulted in significantly increased 
fracture callus mineralization four weeks later (112). 
While exciting, these results have also highlighted the need for more realistic in 
vitro models of the fracture healing environment. In vitro studies of the effects of TNF -a 
on osteogenic differentiation have been complicated by the fact that two supplements 
typically used to stimulate in vitro MSC osteogenic differentiation, dexamethasone and 
ascorbic acid, antagonize TNF-a signaling (14, 62, 158). In fact, when added to this 
typical osteogenic medium, TNF-a had the opposite effect of that seen in vivo - it 
suppressed in vitro MSC osteogenic differentiation (162, 163). One strategy to overcome 
this limitation has been to preculture MSCs in osteogenic supplements and then 
administer TNF -a afterwards. In the absence of dexamethasone, TNF -a has been shown 
to stimulate dose-dependent increases in the alkaline phosphatase (ALP) activity and 
mineralized matrix deposition, which are, respectively, early and late markers of 
osteogenesis (14, 112, 159-161). 
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In a continued effort to better model the function of TNF -a in the fracture healing 
microenvironment, this study investigated the interplay of bone-like extracellular matrix 
(ECM) and TNF -a on MSC osteogenic differentiation. Although the bone ECM is mainly 
composed of mineralized deposits, the fracture microenvironment contains a hematoma 
rich in molecular signaling sources including: insoluble macromolecules (e.g., collagen), 
soluble proteins (including growth factors and cytokines ), as well as proteins and 
receptors on the surfaces of neighboring cells (105, 192). Our laboratory has previously 
described a method to coat microfiber meshes with bone-like, mineralized ECM 
containing an array of osteogenic growth factors (6, 9, 180). The presence of preformed 
bone-like ECM has been shown to transform osteoconductive microfiber scaffolds into 
osteoinductive materials (6, 7, 9-11). 
To create a more realistic in vitro model of the injured bone microenvironment 
and to elucidate the interplay of TNF-a and bone-like ECM, this study investigated the 
impact of varying doses of TNF-a delivered to osteogenically differentiating MSCs 
cultured on 3D biodegradable microfiber scaffolds containing pregenerated bone-like 
ECM. The objective of this study was to determine the impact of bone-like ECM on the 
concentration and temporal pattern of TNF -a delivery that enhances in vitro osteogenic 
differentiation of MSCs. 
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6.2. Methods and Materials 
6.2.1. Experimental Design 
The study design required the culture of two separate batches of MSCs on each 
electrospun poly(B-caprolactone) (PCL) scaffold: one batch to generate the bone-like 
extracellular matrix (ECM), and a second batch for the actual experiment (Figure 6.1) 
PCL 
250,000 
cells/scaffold 
+dex 
PCUECM 
Decellularization 
Experimental 
Groups 
Figure 6.1: Overall study design using pregenerated bone-like ECM. 
Mesenchymal stem cells (MSCs) were isolated from rat bone marrow and cultured on 
electrospun PCL scaffolds in the presence of dexamethasone ( +dex) and complete 
osteogenic media, which has been shown to stimulate production of bone-like ECM. 
These MSCs were removed and then replaced with a second batch of freshly isolated 
MSCs, which were subjected to the experimental conditions shown in Figure 6.2 
A design with 7 groups and 3 time points was used to evaluate the impact of 
pregenerated bone-like ECM on the optimal TNF-a dose for rat MSC osteogenic 
differentiation (Figure 6.2). Based on the previous findings (see previous chapter) of very 
low TNF -a-induced mineralization under the current culture conditions, we selected 
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continuous TNF -a delivery as a temporal pattern because it triggered the highest amount 
of mineralization (other than the positive control) in the temporal variation study (see 
Figure 5.5). The three experimental groups received varying concentrations of TNF-a 
(0.1 ng/ml, 5 ng/ml, 50 ng/ml), that were identical to those in previous studies of MSCs 
on plain PCL scaffolds (see previous two chapters and (14)). 
Precu/ture 
MSC 
harvest 
LowTNF 
Medium 
High TNF 
MSCs on PCUECM 
DayO 
d4 d8 
Figure 6.2: Schematic of study design for ECM and TNF -a interplay. 
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The four control groups consist of two negative controls seeded with MSCs precultured 
in "+dex" media (as shown) or in "-dex" media; a positive control seeded with MSCs 
precultured in "+dex" media that continued to receive dexamethasone during days 0-16, 
and a group of acellular PCL/ECM scaffolds. OM = Osteogenic Media (a-MEM, 10% 
v/v fetal bovine serum, 50 J..Lg gentamicin/ml, 0.5 J..Lg amphotericin-B/ml, 10 mM ~­
glycerophosphate, 50 J.tg/ml ascorbic acid) either with or without 1 o-8 M dexamethasone 
("+dex" vs. "-dex"). 
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Four control groups were included: a positive control seeded with MSCs precultured in 
complete (+dex) osteogenic media that continued to be supplemented with 
dexamethasone during the study; two negative controls cultured in dexamethasone-free 
media that differed in terms of the MSCs seeded (one group had MSCs precultured in 
+dex osteogenic media and the other had MSCs precultured in-dex media); and a group 
of acellular PCL/ECM scaffolds that were "cultured" in -dex media. This fmal group was 
included because similar ECM -coated scaffolds have been previously shown to undergo 
non-cell-specific scaffold calcium accumulation (11). 
6.2.2. Electrospun PCL preparation 
Electrospun PCL meshes were generated according to an established protocol 
(14). The PCL (Lactel, Pelham, AL) had a number-average molecular weight (Mn) of 
59,000 ± 800 Da and polydispersity index (Mw!Mn) of 2.01 ± 0.03, determined via gel 
permeation chromatography (Phenogel Linear Column with 5 J.Lin particles, Phenomenex, 
Torrance, CA; Differential Refractometer 410, Waters, Milford, MA) and a calibration 
curve generated from polystyrene standards (Fluka, Switzerland). A 10 ml syringe was 
loaded with an 18 w/w% solution ofPCL in 5:1 (by vol) chloroform:methanol, fitted with 
a 16 gauge blunt-tip needle (Brico Medical Supplies, Inc., Metuchen, NJ), and positioned 
in the electrospinning apparatus so that the needle tip was 33 em from a glass collecting 
plate placed over the system's grounded copper plate. A detailed description of this 
electrospinning apparatus has been published previously (14, 179). A voltage difference 
of 33 kV was applied to the needle tip and to a copper ring placed 4 em from the needle 
tip. The PCL solution was pumped out of the needle at 40 mllh using a syringe pump 
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until a -1mm thick electrospun mesh was generated. All scaffolds used in this study were 
derived from two electrospun meshes. 
Scaffolds with 8 mm diameter were cut from the meshes using biopsy punches 
(Miltex, York, P A). The thickness of each scaffold was measured using digital micro-
calipers (Mitutoyo, Aurora, IL) and, for consistency with previous work (previous 
chapters as well as (14)), scaffolds with thickness 0.90-1.10 mm were used for the study. 
To prevent degradation or changes to the scaffold surface, electrospinning was performed 
two days prior to MSC seeding, which allowed just enough time to sterilize and prewet 
the scaffolds. 
6.2.3. Scaffold Characterization 
Scaffolds (n = 3) from each of the two electrospun meshes used in this study were 
mounted onto aluminum stubs, sputter-coated with 20 nm of platinum, and imaged using 
scanning electron microscopy (SEM) (FEI Quanta 400 Environmental, Hillsboro, OR) at 
a 7.0 kV accelerating voltage and 2.5 spot size. Predefined coordinates on each scaffold 
were imaged and the diameters of (n = 45 fibers) from the top and (n = 45 fibers) from 
the bottom of each mesh were measured using an established protocol (14, 179). The 
porosity of n = 50 scaffolds from each mesh was determined via an established 
gravimetric analysis protocol (14, 179). 
6.2.4. Preparation of ECM-Coated Scaffolds 
All MSC isolations were approved by the Rice University Institutional Animal 
Care and Use Committee and adhered to the National Institutes of Health guidelines. Two 
batches of cells were required for this study (see Figure 6.1) and were obtained from 
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separated MSC isolations. MSCs were isolated from the pooled femoral and tibial bone 
marrow of male syngeneic Fischer 344 rats weighing 150-175 g, according to established 
methods (8, 9). The MSCs from the first isolation (n = 8 rats) were used to generate the 
bone-like ECM. The bone marrow suspensions from this isolation were cultured in 75 
cm2 cell culture flasks using +dex complete osteogenic media: a-MEM (Gibco, Carlsbad, 
CA) with 10% v/v fetal bovine serum (Gemini Bio-Products, West Sacramento, CA), 50 
f.!g/ml gentamicin, 0.5 f.!g/ml amphotericin-B, 10 mM ~-glycerophosphate, 50 J.1g/ml 
ascorbic acid, and 1 o-s M dexamethasone (Sigma, St. Louis, MO). As in previous studies, 
the medium was changed after one day and the non-adherent cells removed. The adherent 
cells were designated as "mesenchymal stem cells," based on the established osteogenic 
potential of this cell population under appropriate in vitro conditions (3, 14, 183). 
Thereafter, media was changed every two days. MSCs were cultured for a total of 7 days 
until nearly confluent and then seeded onto PCL scaffolds. 
Prior to MSC seeding, and immediately after being punched from freshly 
electrospun meshes, the PCL scaffolds were sterilized via exposure to ethylene oxide gas 
for 14h and prewet using a decreasing ethanol gradient (from 100% to 70%), according to 
established protocols (14, 179). The ethanol was exchanged with sterile milliQ water, and 
then with sterile +dex media. The scaffolds (in media) were stored at 37°C overnight. 
The next day, the scaffolds were press-fit into sterile seeding cassettes and placed into 
ultra-low attachment 6-well plates (1 cassette/well) (Corning Incorporated Life Sciences, 
Lowell, MA) for seeding. 
On the day of seeding, the nearly confluent MSCs were detached with 0.25% 
trypsin/EDTA (Gibco, Carlsbad, CA), counted with a hemocytometer, centrifuged, and 
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resuspended at 1.25 million cells/ml in +dex osteogenic media. 0.2 ml of the resuspended 
MSCs were added drop-wise to each seeding cassette containing a press-fit scaffold. 
After a 4h attachment period, each well was filled with 8 ml of +dex media. After 
24h, the constructs were moved to fresh ultra-low attachment 6 well plates containing 4 
ml of fresh +dex media (1 scaffold/well). The constructs were cultured for 12 days total, 
with media changes every two days. 
After 12 days, all scaffolds were removed from the media and rinsed twice with 4 
ml of phosphate-buffered saline (PBS). For baseline calcium measurements, (n = 4) 
constructs were each placed into 1 ml of sterile milliQ water and flash-frozen. These 
constructs were stored at -20°C in a non-defrosting freezer until the day 4 timepoint, 
when they were decellularized and their calcium content was quantified in parallel to that 
of the day 4 samples. The remaining constructs were immediately decellularized 
according to an established protocol (9) to create the PCL/ECM scaffolds that were used 
for the experiment. Briefly, the scaffolds were placed in 1.5 ml sterile milliQ water, flash-
frozen, and stored at -20°C overnight. The next day, the scaffolds were thawed at 37°C 
for 10 min, rinsed twice with 2 ml PBS, and then placed in 1.5 ml fresh sterile milliQ 
water. Aseptic techniques were used for all steps. The entire freeze (this time using liquid 
nitrogen for 10 min)/thaw (37°C for 10 min)/rinsing cycle was repeated two more times, 
and then the (now decellularized) PCL/ECM scaffolds were press-fit into sterile seeding 
cassettes. Each seeding cassette was placed into the well of a sterile ultra-low attachment 
6-well plate (Corning) for MSC seeding. 
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6.2.5. MSC Isolation for TNF -a Culture 
On the sixth day of ECM pregeneration, a new batch of MSCs were isolated from 
the pooled femoral and tibial bone marrow of (n = 6) male syngeneic Fischer 344 rats 
weighing 150-175 g, according to established methods (8, 9). The bone marrow 
suspensions from each rat were split into two portions and cultured in either +dex or -dex 
media (equivalent to +dex media except that it lacks dexamethasone) in fresh 75 cm2 
culture flasks. As for the previous isolation, non-adherent cells were removed after 24h 
and the MSCs were cultured for 7 days total. 
On the day of seeding, which was the same day that the decellularized PCL/ECM 
scaffolds were prepared, the nearly confluent MSCs were detached with 0.25% 
trypsin!EDTA (Gibco, Carlsbad, CA), counted with a hemocytometer, centrifuged, and 
resuspended at 1.25 million cells/ml in -dex osteogenic media. The cells that had been 
precultured in -dex media were lifted and resuspended separately from those precultured 
in +dex media. For the MSCs precultured in -dex media, 0.2 ml of the cell suspension 
were added to (n = 13) PCLIECM scaffolds; this was the -dex/-dex control group (see 
Figure 6.2). For the acellular group, (n = 13) PCL/ECM scaffolds were press-fit into 
seeding cassettes but were not seeded with any MSCs. The remaining PCL/ECM 
scaffolds were seeded with +dex-precultured cells (0.2 ml cell suspension/scaffold, 
corresponding to 0.25 million cells/scaffold). 
After allowing 4h for cell attachment, each well was filled with 8 ml of -dex 
media and the relevant groups (see Figure 6.2) were supplemented with either 
dexamethasone (to achieve a 10-8 M concentration) or 4 !J.Vwell of the appropriate TNF-a 
stock solution. 
120 
6.2.6. TNF -a Reconstitution and Dilution 
Recombinant rat TNF-a (R&D Systems, Minneapolis, MN) was reconstituted at 
100 ng/J..tl on the day of scaffold seeding using sterile PBS containing 0.1 w/w% bovine 
serum albumin (Sigma), according to the manufacturer's instructions. The stock solution 
was then further diluted to prepare 0.1 ng/J..tl, 5 ng/J..tl, and 50 ng/J..tl stock solutions. For 
experiments, 4 J..tl of TNF -a stock solution were added to 4 ml of media used for construct 
culture, resulting in the desired 0.1 ng/ml, 5 ng/ml, or 50 ng/ml TNF-a. 
6.2.7. Cellularity, Alkaline Phosphatase Activity, and Calcium Content Assays 
On days 4, 8, and 16 of the culture of the second batch of MSCs on PCL/ECM 
(see Figure 6.1), (n = 4) scaffolds from each group were removed, rinsed twice with 4 ml 
of PBS, and flash-frozen in 1 ml of sterile milliQ water using liquid nitrogen. The cells 
were lysed using three consecutive freeze/thaw/sonication cycles (10 min at -so·c, 10 
min at 3TC, 10 min sonication). The DNA content of each resulting cell lysate was 
quantified using the fluorometric PicoGreen assay (Molecular Probes, Eugene, OR) and 
then converted to the number of cells per construct (9, 14). The alkaline phosphatase 
(ALP) activity of the cell lysates was quantified using an established colorimeteric assay 
based on the rate of conversion of the colorless substrate p-nitrophenyl phosphate 
disodium salt hexahydrate (Sigma), to a yellow product,p-nitrophenol (9, 14). Next, each 
construct was transferred into 1 ml 1 N acetic acid and left on a shaker table at 200 rpm 
overnight to dissolve matrix-bound calcium. Calcium content was quantified using an 
established colorimetric assay that is based on the Arsenazo III calcium chelating agent 
(Genzyme Diagnostics PEl, Charlottetown, Prince Edward Island, Canada). Samples and 
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standards were run in triplicate for all assays. Samples were diluted as necessary to fall 
within the range of the standards for each assay. A detailed experimental procedure for 
each of these biochemical assays is provided on pages 58-59 and has also been published 
(9, 14). 
6.2.8. Sample Preparation for Histology and SEM 
At the final timepoint, n = 1 construct from each of the seven groups was rinsed 
twice with PBS and cut in half with a sterile razorblade. One half of each construct was 
prepared for SEM via fixation in 2.5% glutaraldehyde (Sigma) overnight and then 
dehydration through an ascending ethanol gradient (70% to 100%). The samples were 
air-dried overnight, mounted on aluminum stubs, coated with platinum, and imaged with 
SEM as described above (see "Scaffold Characterization"). 
The other half of each construct was fixed overnight in 5 ml of 10% buffered 
formalin phosphate (Fisher Scientific, Pittsburgh, P A), passed through an ascending 
ethanol gradient (70% to 100%), and embedded in HistoPrep (Fisher Scientific) overnight 
at room temperature. Frozen 5 J.tm thick sections were cut with a cryotome (CM1850, 
Leica Microsystems, Bannockburn, IL), placed on Superfrost Plus slides (VWR, Radnor, 
P A), and incubated at 45°C on a slide wanner for 4-5 days to achieve optimal section 
adhesion (14). 
On the day of histological staining, the sections were rehydrated with water. The 
slides were then flooded with von Kossa stain (5% w/w silver nitrate (Sigma) in milliQ 
water) and kept under an ultraviolet (UV) lamp for 30 min. The slides were rinsed with 
water and then 95% ethanol. Alcoholic eosin Y (Sigma) was applied as a counter-stain 
for 3 min. The slides were rapidly dehydrated and cleared with 95% ethanol, and then 
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imaged with a light microscope (Eclipse E600, Nikon, Melville, NY) equipped with a 
camera (3CCD Color Video Camera DXC-950P, Sony, Park Ridge, NJ) and image-
capture software. Light microscope images were calibrated using the standard two-image 
method to correct for differences in background lighting and in dark -current effects in the 
detector (185). 
6.2.9. Statistical Analysis 
Fiber diameters and porosities are reported as mean ± standard deviation for n = 
45 fibers and n = 50 scaffolds, respectively. The average fiber diameter of the top and 
bottom of each PCL microfiber mesh, along with the average porosity, were compared 
using a Student's t-test for two independent samples with equal variance (a= 0.05) after 
performing an F -test to validate the assumption of equal variance at 95% confidence. 
Cellularity, ALP activity, and calcium assay results are reported as mean ± standard 
deviation for n = 4 constructs. Statistical amongst groups at each time point, and also 
within each group over time, were analyzed at 95% confidence using one-way analysis of 
variance. Multiple pair-wise comparisons were made using the Bonferroni post-hoc 
analysis method at 95% confidence. 
6.3. Results and Discussion 
6.3.1. Electrospun PCL morphology 
The morphology of representative scaffolds from this study is shown in Figure 
6.3, imaged via SEM at varying magnifications. The top surfaces of the PCL microfiber 
meshes, which were seeded with MSCs, had statistically equivalent mean fiber diameters 
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(p > 0.05), as shown in Table 6.1. However, one mesh had a slightly higher mean fiber 
diameter at the bottom ( ~ 14 J...lm). Despite this minor differences, the two electro spun 
PCL microfiber meshes fabricated for this study had statistically equivalent mean 
porosities (p > 0.05) (Table 6.1 ). 
Figure 6.3: Representative scaffold morphology via SEM. 
Representative scaffolds from the electrospun PCL meshes generated for this study, 
imaged via SEM at varying magnifications, (a) 300x, (b) 600x , and (c) 2000x. Scale bars 
for (a,b) are 100 J...Lm, while the scale bar (c) is 20 J...Lm. 
Table 6.1 Comparison of fiber diameters and porosites for the two electrospun 
meshes used for this study. 
Parameter for Comparison Value for Mesh 1 Value for Mesh 2 
Fiber Diameter, Top (pm) 10.9 ± 2.0 11.8 ± 1.2 
Fiber Diameter, Bottom (pm) 11.3 ± 1.4* 13.6 ± 2.4* 
Porosity (0/o) 80.6 ± 2.1 80.1 ± 2.0 
Values are presented as mean ± standard deviation. The sample size was n = 45 for fiber 
diameters from the top and bottom of each mesh, and n = 50 scaffolds for PCL mesh 
porosity. *indicates pairs of values that significantly differ (p < 0.05). 
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6.3.2. PCL/ECM construct cellularity 
Figure 6.4 depicts the construct cellularity at each timepoint. When the same 
treatment groups were cultured on plain PCL (Figure 5.7a), all groups had similar day 4 
and day 8 cellularity, with the exception of the +dex-precultured negative control (0 
ng/mL TNF), which had a much higher cell count than all other groups on day 8. 
In contrast, the presence of bone-like ECM suppressed the proliferation of the 
negative control groups (0 ng/mL TNF and 0 ng/mL TNF (pre: -dex) in Figure 6.4) 
compared to plain PCL (+dex/-dex and -dex/-dex, respectively, in Figure 5.3). The 
cellularity of the positive control was fairly similar on both PCL/ECM and plain PCL, 
and the acellular constructs ("Acellular") had nearly zero cells at all timepoints, as 
expected. 
On PCL/ECM, MSCs supplemented with TNF -a had slightly higher day 4 and 
day 8 cell counts, and much lower day 16 values (Figure 6.4), compared to the analogous 
groups on plain PCL scaffolds (Figure 5.7a). The presence of bone-like ECM, combined 
with TNF -a, appears to have stimulated MSC proliferation at the early timepoints, and 
slowed proliferation between days 8-16 (Figure 6.4). 
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Figure 6.4: MSC cell count on preformed ECM and varying TNFa dose 
Scaffolds with pregenerated bone-like ECM (PCL/ECM) were seeded with MSCs 
precultured in +dex media (except for the group designated "(pre: -dex)," which was 
seeded with MSCs precultured in -dex media). Experimental groups were exposed to 
varying TNF -a doses. The control groups included acellular PCL/ECM, a positive control 
cultured in +dex media (0 ng/mL +dex), and two negative controls cultured in-dex media 
(0 ng/mL TNF) containing MSCs precultured in either +dex or -dex media (the latter is 
denoted with "pre: -dex"). Bars represent average ± standard deviation of (n = 4) 
scaffolds per group at each timepoint. Within a timepoint, groups with * differ from all 
other groups (p < 0.05), while letters A-D indicate groups that differ from all other 
groups but not groups with the same letter (p < 0.05). On day 16, + indicates that d4 and 
dl6 values of that group differ (p < 0.05), while # indicates that values at all timepoints 
differ (p < 0.05). 
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6.3.3. PCL/ECM construct ALP activity 
The presence of preformed ECM greatly increased the ALP activity of all groups 
by several fold, which is particularly evident in comparing the y-axis of Figure 6.5b 
(maximum value: 55 pmol/hour/cell) to that of Figure 5.7c (maximum value 15 
pmol/hour/cell). The most prominent change was in the acellular constructs, which had 
much higher ALP activity on PCL/ECM (Figure 6.5a) compared to plain PCL (Figure 
5.7b), despite near-zero cellularity (Figure 6.4). The ALP detected on the acellular 
PCL/ECM constructs likely reflects ALP secreted by the flrst batch of MSCs, which 
generated the ECM. Studies of native rat bone have shown that ALP exists in both a 
membrane-bound form, on the external surface of osteoblasts, and also as a free 
extracellular enzyme localized near the collagen fibers of mineralizing osteoid (193). It is 
likely that the values for the acellular group in Figure 6.5 reflect the activity of this latter 
"free" ALP, since nearly complete decellularization of the PCL/ECM was achieved 
(Figure 6.4). 
In contrast to the monotonic increasing trends observed on plain PCL for the 
negative control groups (see "+dex/-dex" and "-dex/-dex" in Figure 5.4), as well as for 
the 0.1 ng/mL TNF group (see group with same name in Figure 5.7c), the ALP activity 
per cell for each of these groups on PCL/ECM was fairly constant on days 4-8 and then 
slightly increased by day 16 (see "0 ng/mL TNF," "0 ng/mL TNF (pre: -dex)," and "0.1 
ng/mL TNF" groups in Figure 6.5b ). 
Aside from the change in the magnitude of the ALP activity values, the positive 
control group (0 ng/mL +dex) and the 5 and 50 ng/mL TNF groups had the same trends 
in ALP activity on plain PCL and on PCL/ECM: a monotonic increase in ALP activity 
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for the positive control, and a monotonic decrease for the 5 and 50 ng/mL TNF groups. 
On both plain PCL (Figure 5.7b) and PCL/ECM (Figure 6.5a), the ALP activity per 
scaffold for the 5 and 50 ng/mL TNF groups was indistinguishable from that of the 
acellular constructs on days 8 and 16, suggesting that the increased ALP values on 
PCL/ECM were due to the extracellular ALP, which was not affected by TNF -a. 
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Figure 6.5: ALP activity of MSCs on preformed ECM with varying TNF -a dose -
continued on next page. 
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Figure 6.5: ALP activity ofMSCs on preformed ECM with varying TNF-a dose 
Scaffolds with pregenerated bone-like ECM (PCL/ECM) were seeded with MSCs 
precultured in +dex media (except for the group designated "(pre: -dex)," which was 
seeded with MSCs precultured in -dex media). ALP activity on a per scaffold basis is 
shown in (a), while the same data on a per cell basis is shown in (b) with the exception of 
the acellular group. Experimental groups were exposed to varying TNF -a doses. The 
control groups included acellular PCL/ECM, a positive control cultured in +dex media (0 
ng/mL +dex), and two negative controls cultured in -dex media (0 ng/mL TNF) 
containing MSCs precultured in either +dex or -dex media (the latter is denoted with 
"pre: -dex"). Bars represent average± standard deviation of (n = 4) scaffolds per group at 
each timepoint. Within a timepoint, groups with* differ from all other groups (p < 0.05), 
while letters A-F indicate groups that differ from all other groups but not groups with the 
same letter (p < 0.05). On day 16, + indicates that d4 and d16 values of that group differ 
(p < 0.05), while# indicates that values at all timepoints differ (p < 0.05). 
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6.3.4. PCL/ECM construct mineralization 
The baseline calcium content of the PCL/ECM was 140 ± 13 J..Lg Ca2+/scaffold, 
which is indicated by the dashed line in Figure 6.6. Comparison to the analogous study 
on plain PCL scaffolds (Figure 5. 7 d) indicates that the presence of pre generated ECM 
stimulated a huge increase in the calcium values of all groups. 
The presence of ECM caused the acellular constructs to accumulate calcium at a 
rapid, linear rate (-23 J..Lg/day). This phenomenon has been previously reported for PCL 
micro fiber scaffolds with smaller fiber diameter ( ~5 Jlm, compared to ~ 1 0 J..Lm in this 
study) that were coated with ECM generated under similar in vitro culture conditions 
(11). Remarkably, despite the presence of ECM, the dexamethasone-naive negative 
control group (0 ng/mL TNF (pre: -dex)) ceased to mineralize between days 4 and 8. 
Although some calcium deposition occurred between days 8 and 16, this group had the 
lowest calcium content at the final timepoint (p < 0.05). This type of negative control was 
not included in the previous study of PCL/ECM (11 ), which only included a negative 
control with MSCs precultured in +dex media (analogous to the "0 ng/mL TNF" group in 
Figure 6.6) . The low calcium content of the "0 ng/mL TNF (pre: -dex)" negative control 
indicates that the presence of dexamethasone-naive cells and/or the ECM secreted by 
these cells inhibited the non-cell-specific calcium accumulation of the pregenerated 
ECM. This suggests that the dexamethasone-naive (0 ng/mL TNF (pre: -dex)) constructs 
may be a superior negative control compared to acellular PCL/ECM, since all other 
groups also contain cells, which would also presumably reduce non-cell-specific calcium 
accumulation. 
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Figure 6.6: MSC calcium deposition on PCL/ECM with varying TNF -a dose 
The baseline calcium content of the PCL scaffolds with pregenerated bone-like ECM 
(PCL/ECM) was 140 ± 13 J.tg Ca2+/scaffold, which is indicated by the dashed line. 
PCL/ECM scaffolds were seeded with MSCs precultured in +dex media (except for the 
group designated "(pre: -dex)," which was seeded with MSCs precultured in-dex media). 
Experimental groups were exposed to varying TNF -a doses. The control groups included 
acellular PCL/ECM, a positive control cultured in +dex media (0 ng/mL +dex), and two 
negative controls cultured in-dex media (0 ng/mL TNF) containing MSCs precultured in 
either +dex or -dex media (the latter is denoted with "pre: -dex"). Bars represent average 
±standard deviation of (n = 4) scaffolds per group at each timepoint. Within a timepoint, 
groups with * differ from all other groups (p < 0.05), while letters A-C indicate groups 
that differ from all other groups but not groups with the same letter (p < 0.05). On day 
16, + indicates that d4 and dl6 values of that group differ (p < 0.05), while # indicates 
that values at all timepoints differ (p < 0.05). 
The +dex-precultured negative control (0 ng/mL TNF) constructs had slightly 
higher calcium content than the positive control group (0 ng/mL TNF +dex) at both of the 
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early timepoints (p > 0.05; Figure 6.6), which greatly differed from the pattern observed 
on plain PCL (Figure 5.7d) where the positive control had much greater calcium content 
at all timepoints (p < 0.05). By day 16, the calcium content of both the positive control (0 
ng/mL TNF +dex) and the +dex-precultured negative control (0 ng/mL TNF) exceeded 
that of the acellular PCL/ECM constructs (p > 0.05; Figure 6.6). A similar pattern was 
observed in the previous study of ECM-coated 5 J..Lm PCL microfibers, although the 
pattern of per cell ALP activity in that study differed from that shown in Figure 6.5b in 
that both groups exhibited peak ALP activity on day 8 (11). 
The presence of pregenerated ECM greatly altered the calcium deposition in 
response to varying doses of TNF -a. In the analogous study on plain PCL (Figure 5. 7 d), 
all doses of TNF-a stimulated day 4 calcium deposition that was greater (p < 0.05) than 
that of the negative control (0 ng/mL TNF) and equivalent to that of the positive control 
group (0 ng/mL TNF +dex). In that same study, from days 4-8, the higher TNF-a doses 
(5 and 50 ng/mL TNF) continued to stimulate calcium deposition that exceeded that of 
the negative control (p < 0.05) and was equivalent to that seen with dexamethasone (0 
ng/mL +dex), although by day 16 the positive control group had much higher calcium 
content (p < 0.05) than the TNF-a groups (Figure 5.7d). In contrast, on PCL/ECM, the 
highest dose of TNF-a (50 ng/mL TNF) resulted in day 4 calcium content that was 
slightly higher than that of the positive control (p = 0.08), but equivalent to that of the 
+dex-precultured negative control (0 ng/mL TNF) and the acellular constructs (Figure 
6.6). On day 8, as seen on plain PCL, the constructs exposed to higher doses ofTNF-a (5 
and 50 ng/mL TNF) had equivalent calcium content to the positive control (0 ng/mL 
+dex). However, in contrast to plain PCL, this calcium content was also equivalent to that 
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of the +dex-precultured negative control (0 ng/mL TNF) and yet significantly exceeded 
(p < 0.05) the calcium deposition of the 0.1 ng/mL TNF group. Thus, comparing the day 
8 calcium values on plain PCL (Figure 5.7d) and PCL/ECM (Figure 6.6) indicates that 
the presence of ECM reduced the impact of both dexamethasone and the higher doses of 
TNF -a. This may reflect complex signaling from the ECM molecules. SEM imaging 
(Figure 6.7) and histology (Figure 6.8) confirmed that cells and matrix coated the 
surfaces of the scaffolds and also penetrated into the pores between the PCL fibers. 
The difference between TNF -a effect on MSCs cultured on plain PCL and on 
PCL/ECM constructs was most evident at the final timepoint. TNF -a caused a dose-
dependent increase in day 16 calcium content on plain PCL (p < 0.05; Figure 5.7d), and a 
dose-dependent decrease in calcium content on PCL/ECM (p < 0.05; Figure 6.6). The 
dose-dependent decrease seen in this study differs from the results of previous studies of 
osteoprogenitors cultured in vitro and exposed to TNF -a in the absence of 
dexamethasone; in those studies, TNF-a stimulated a dose-dependent increase 1n 
mineralized matrix deposition (14, 112, 159-161). However, with the exception of one 
study (14), in which MSCs were cultured on 3D plain PCL microfiber meshes, all of 
these other studies involved delivery of TNF-a to cells cultured in 2D (112, 159-161). 
Thus, the effects noted in this study likely reflect the interplay of the 3D bone-like ECM 
and TNF-a. 
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Figure 6.7: Surface morphology ofPCL/ECM after 16 days of culture 
On the final day of the study, the surface of one half of a representative scaffold from 
each group was imaged via SEM. Images in each row are from the same group, and 
images in each column have the same magnification (with the exception of the right-most 
column). Specifically, the images depict: (a-d) the positive control (0 ng/mL +dex in 
other Figures); (e-i) the negative control cultured in-dex media (0 ng/mL TNF); (j-m) the 
negative control seeded with dexamethasone-naive MSCs and cultured in-dex media (0 
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ng/mL TNF (pre: -dex)); and (n-q) acellular PCL/ECM (Acellular). The final three rows 
of images depict the experimental groups cultured with varying doses of TNF-a: (r-v) 0.1 
ng/ml, (w-a) 5 ng/ml, and (~-s) 50 ng/ml. The original magnification of the images in the 
columns (from left to right) is: 34x (scale bar is 1 mm), 200 x (scale bar is 200 J...Lm), 400 x 
(scale bar is 100 J...Lm), 1 OOOx (scale bar is 25 J...Lm). The images in the final column were 
taken at 1 OOO x (scale bar is 25 J...Lm), except for (i) which was taken at 2000 x (scale bar is 
15 J...Lm). For all columns except for the right-most column, the scale bars at the top and 
bottom of each column apply to all images within that column. 
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Figure 6.8: Construct cell and mineral distribution visualized by histology 
Representative cross-sections of MSC-seeded PCL/ECM scaffolds after 16 days of 
culture. MSCs were precultured in complete osteogenic media ( +dex) or 1n 
dexamethasone-free media (-dex). The positive control (+dex/+dex) continued to receive 
dexamethasone after MSCs were seeded onto the scaffold. All other MSC/scaffold 
constructs were cultured in dexamethasone-free media. Experimental groups shown were 
continuously supplemented with 0.1, 5, or 50 ng/ml TNF-a (abbreviated "TNF" in the 
figure). 5 J...Lm thick sections were stained with von Kossa, which stains mineralized 
matrix black (blue arrows), and eosin, which stains cells and non-mineralized matrix 
reddish-pink (yellow arrows). Images were captured at lO x original magnification. Scale 
bar in the lower right corner represents 200 J...Lm and applies to all images. 
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As previously observed in a similar 3D culture system containing biodegradable 
microfibers coated with bone-like ECM (11), MSCs cultured on PCL/ECM continued to 
undergo osteogenic differentiation and deposit mineralized matrix in the absence of 
dexamethasone (Figure 6.6 and Figure 6.8). This is remarkable because dexamethasone is 
typically required for in vitro osteogenic differentiation of MSCs ( 4). However, since 
corticosteroid signaling is not involved in in vivo bone regeneration, and may even inhibit 
fracture healing (128, 191), our findings suggest that culture on 3D PCL/ECM constructs 
is a better model of in vivo MSC osteogenic differentiation. 
The findings of this study with respect to TNF -a may be a reflection of the fact 
that PCL/ECM constructs are a more realistic model of the in vivo fracture 
microenvironment. Although TNF-a signaling is critical for in vivo bone regeneration (1), 
the distinct temporal pattern of its expression cannot be ignored (see Figure 2.1). In 
murine models, TNF-a signaling peaks 24h following bone injury, returns to baseline 
levels after a few days, and then rises again several weeks later (59). In a recent study of 
a fracture healing model, daily local injections of TNF -a during the first two days after 
bone fracture significantly increased fracture callus mineralization four weeks later (112). 
However, chronic exposure to high levels of TNF-a has damaging effects on in vivo 
fracture healing, including decreased bone volume and reduced bone mechanical strength 
(120). The pattern of mineralized matrix deposition seen on PCL/ECM is consistent with 
these in vivo findings. At early timepoints, high doses of TNF -a did not adversely affect 
calcium content. However, 16 days of continuous TNF -a delivery caused a dose-
dependent decrease in mineralized matrix deposition (Figure 6.6). These results for TNF-
a highlight the exciting potential of PCL/ECM constructs as a more clinically realistic in 
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vitro culture model to Improve our understanding of the in vivo effects of various 
cytokines. 
6.4. Conclusions 
This study demonstrated that continuous delivery of the pro-inflammatory 
cytokine TNF -a over 16 days reduces mineralized matrix deposition, a late stage marker 
of osteogenic differentiation, when delivered to MSCs cultured in 3D electrospun PCL 
microfiber meshes coated with pregenerated bone-like ECM ("PCL/ECM"). As 
previously observed in a similar 3D culture system, MSCs cultured on PCL/ECM 
continued to undergo osteogenic differentiation and deposit mineralized matrix in the 
absence of dexamethasone. Exposure to TNF -a for 4-8 days caused a dose dependent 
decrease in cell-specific ALP activity, which is an early marker of osteogenic 
differentiation, and did not adversely affect mineralized matrix deposition. However, 
continuous TNF -a delivery over 16 days markedly reduced calcium deposition compared 
to the untreated control group. These results simulate the in vivo response to TNF -a, 
where brief, highly regulated signaling stimulates bone regeneration, while prolonged 
signaling has damaging effects on bone. Thus, this study underscores the exciting 
potential of PCL/ECM constructs as a more clinically realistic in vitro culture model to 
improve our understanding of the impact of various cytokines on MSC osteogenic 
differentiation, which will ultimately facilitate the design of new tissue engineering 
strategies to rationally control inflammation and promote bone regeneration. 
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